Molecular mechanisms of Foxp3-mediated gene regulation and their contribution to T cell and thymic epithelial cell function by Hench, Virginia Kathleen
MOLECULAR MECHANISMS OF FOXP3-MEDIATED GENE REGULATION AND THEIR 
CONTRIBUTION TO T CELL AND THYMIC EPITHELIAL CELL FUNCTION 
 
 
 
 
 
Virginia K. Hench 
 
 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the   
Department of Microbiology and Immunology. 
 
 
 
 
 
Chapel Hill, NC 
2010 
 
 
 
 
 
 
 
 
 
 
Approved by: 
Advisor: Lishan Su 
Reader: Jonathan Serody 
Reader: Jeffrey A. Frelinger 
Reader: Jenny Ting 
Reader: Roland Tisch 
Reader: Karen P. McKinnon 
 ii 
ABSTRACT 
VIRGINIA K. HENCH: MOLECULAR MECHANISMS OF FOXP3-MEDIATED GENE REGULATION AND 
THEIR CONTRIBUTION TO T CELL AND THYMIC EPITHELIAL CELL FUNCTION 
 
(UNDER THE DIRECTION OF DR. LISHAN SU) 
 
Severe autoinflammatory disease is associated with mutations in the Foxp3 gene in 
mice and humans. Foxp3 is required for the development, function, and maintenance of 
natural regulatory T cells, a subset of thymic-derived CD4pos T cells that suppress T cell 
activation and inflammatory processes. Also, Foxp3 expression and function has been 
reported in thymic epithelial cells (TECs), suggesting a T cell extrinsic function for Foxp31. 
TECs contribute to tolerance and immunity by supporting T cell development. 
In chapter two, I will discuss the interaction between FOXP3 and Siva, a previously 
unknown binding partner of FOXP3. Siva is a pro-apoptotic molecule that is expressed across 
a range of tissues, including CD4posFOXP3pos T cells. FOXP3 interacts with both the Siva-1 
and Siva-2 isoform in 293T cells. The FOXP3-binding domain maps to Siva’s C-terminus. A 
central region of FOXP3 is involved in binding to Siva. Siva repressed IL-2 gene expression 
in Jurkat T cells. Further, I investigated whether Siva and FOXP3 functionally interact to 
repress IL-2 gene expression. The presence of Siva negatively affects the repressive effect of 
FOXP3 on IL-2 gene expression. Lastly, we showed that FOXP3 enhances Jurkat T cell 
apoptosis in unstimulated cells, but protects from apoptosis in response to stimulation with 
PMA and Ionomycin. In summary, the data support the hypothesis that both FOXP3 and Siva 
are negative regulators of T cell activation. 
 iii 
In chapter three, I will present data pertaining to Foxp3 regulation of Her2/neu in 
TECs and the effect of Her2/neu signaling on thymopoiesis. Previously, it was reported that 
Her2/neu is upregulated in TECs from scurfy mice, a Foxp3-deficient strain1. We showed 
that Foxp3 expression was negatively correlated with Her2/neu expression across mouse 
TEC lines. Further, a Her2/neu-specific monoclonal antibody, Herceptin, partially rescued 
defective thymopoiesis in scurfy mice1. To investigate the effect of Her2/neu signaling on 
thymopoiesis, we treated fetal thymic organ cultures (FTOC) with a dual inhibitor of 
Her2/neu and EGFR, GW572016 (GW57). GW57 moderately enhanced thymopoiesis in 
FTOCs, suggesting that GW57 could have therapeutic potential for immunodeficient patients 
such as HIV-1 infected individuals and those who are recovering from intensive cytotoxic 
cancer treatments. 
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CHAPTER ONE 
BACKGROUND AND INTRODUCTION
 2 
FORWARD 
During my time as a graduate student (2003-2010), I studied Foxp3 function in 
thymic epithelial cells (TECs) and regulatory T cells (Tregs), two principal mediators of 
immune regulation and tolerance. TECs contribute to selection of a diverse T cell repertoire 
that is poised to fight foreign invaders and is tolerant to self. Tregs suppress T cell activation 
and inflammatory processes. 
In this introductory chapter, I will briefly outline aspects of the immune system that 
provide a cellular context within which Foxp3 operates. Additionally, I will provide 
background material that informed investigations and hypotheses discussed in subsequent 
chapters. First, I will discuss the concept of immune tolerance and cell-mediated tolerance 
mechanisms. Investigations of the thymus organ, thymopoiesis, TECs, and Tregs shaped our 
understanding of tolerance prior to discovery of Foxp3. Although there are some points of 
deviation, this chapter is loosely organized based on scale, such that explanations of organ 
and tissue function precede molecular function. Thus, detailed discussion of Foxp3 does not 
appear until the second half of this chapter. This chapter concludes with a discussion of Siva, 
a pro-apoptotic protein, which we identified as a FOXP3-binding partner.  
Since its discovery, Foxp3’s contribution to the Treg phenotype has become well 
established. In contrast, Foxp3 expression and function in TECs became controversial during 
the course of my research. For the sake of clarity, the controversy regarding Foxp3 function 
in TECs can be found in Chapter Three, along with background information regarding 
Her2/neu function in TECs. 
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Finally, in this dissertation, I will adhere to a proposed nomenclature whereby the 
mouse and human genes are designated as Foxp3 and FOXP3, respectively. 
 4 
IMMUNE HOMEOSTASIS THROUGH PROTECTION AND TOLERANCE 
IMMUNITY AND INFLAMMATION 
The immune system preserves the integrity of an individual by balancing two 
endeavors that occasionally operate as opposing forces: defense against infection and 
tolerance to the organism’s own tissues. Additionally, without a healthy immune system, 
wounds cannot heal. A healthy immune response can clear tumors before malignancy 
expands, but a chronic unresolved immune response may promote carcinogenesis2. 
Breakdowns in immune regulation mechanisms could be responsible for some aborted 
pregnancies3 and for male infertility4. Multiple tissues, cell lineages and molecular 
mechanisms are involved in the immune response process and its regulation5,6. Immune 
pathogenesis ensues when these processes breakdown. 
Inflammation is the hallmark feature of an activated immune response. The ancient 
Romans described inflammation as rubor, tumor, calor and dolor (redness, swelling, heat and 
pain). In modern times, advanced technologies allow investigation and more precise 
definition of the molecular and cellular mediators that initiate and restrain inflammation. 
While inflammation has protective effects, it can also lead to tissue damage. For example, in 
asthma and inflammatory bowel disease, unresolved inflammation leads to destruction of the 
airway and bowel epithelium, respectively7,8. Generally speaking, acute inflammation is 
protective and chronic inflammation is deleterious as it is linked to oncogenesis and 
autoimmune diseases9. 
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TOLERANCE 
Tolerance is fundamental to balanced immunity. Conceptually, immune tolerance 
describes the immune system’s ability to discriminate and ‘choose’ not to form a response. 
Tolerance is specific and requires a prior encounter with the antigen that one tolerates10. 
Tolerance plays into how the immune system deals with innocuous matter such as non-
pathogenic microbes in the gut and the intrinsically non-toxic substances that induce allergic 
reactions in sensitive individuals8. 
Self-tolerance, the ability to discriminate self from non-self, is one of the most 
important forms of immune tolerance. Self-tolerance requires the removal and suppression of 
adaptive immune cells expressing receptors reactive to self. Paul Ehrlich coined the term 
horror autotoxicus11 to describe a devastating autoimmune Armageddon that was restrained 
by mechanisms he could not explain. Interestingly, Ehrlich did not believe autoimmune 
disease to be possible11. 
Unfortunately, autoimmune diseases are possible and have become quite common in 
developed countries since the middle of the twentieth century12. Autoimmune diseases are 
defined as pathologies resulting from an adaptive immune response against self-antigens6. 
For example, in the nonobese diabetic mouse, an experimental model of type I diabetes, 
pancreatic T cell infiltration requires islet antigen specificity (Comment in 13). In contrast, 
inflammatory bowel disease (IBD) depends on the presence of gut microflora. Although, it is 
a T cell mediated disease, IBD may not actually depend on self-antigen specific T cells14. 
Conceptually, self-tolerance is simple. It is the process of active immune 
unresponsiveness towards one’s self, which is necessary to preserve health. Figuring out how 
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tolerance happens is difficult. The early experimental models used to observe tolerance give 
tangible examples of what tolerance is. 
MEDAWAR’S GRAFT TOLERANCE MODEL 
The classic transplantation models used by Billingham, Brent, and Medawar help 
illustrate how immune tolerance is not passive, but is an active and acquired process15,16. 
Medawar and colleagues performed a series of experiments where CBA mice received either 
cells or skin grafts from genetically distinct (allogeneic) strain A donors. Adult CBA skin 
graft recipients rejected skin grafts from A strain donors at around eleven days post-
transplant. In contrast, if fetal CBA mice were injected with donor A cell suspensions in 
utero, they accepted the allogeneic skin grafts transplanted eight weeks later. The CBA mice 
became tolerant to the donor A skin graft because they were exposed to donor A antigens 
very early in life15,16. 
Subsequent experiments performed by Medawar would show that the initial 
transplant needed to be performed within a time window shortly before or after birth in order 
to achieve graft tolerance17. This same neonatal tolerance window would become relevant 
when Miller started experimenting with thymectomies18 and when Sakaguchi’s group 
investigated the relationship between thymectomy and CD25pos Treg production19. 
CENTRAL AND PERIPHERAL TOLERANCE 
Since Medawar’s landmark experiments, immunologists have broken down tolerance 
mechanisms into two categories: central and peripheral. Central tolerance relies on 
lymphocyte development processes that selectively eliminate cells expressing self-reactive B 
cell receptors and T cell receptors (TCRs). Unfortunately, central tolerance mechanisms are 
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not one hundred percent effective. Peripheral tolerance limits immune activation and 
compensates for self-reactive lymphocytes that escape deletion during central tolerance. 
Peripheral tolerance mechanisms include deletion, anergy, and suppression. Anergy is 
a cell-intrinsic inactivation mechanism that happens after antigen encounter. Anergic T cells 
cannot proliferate or produce cytokines. Impaired IL-2 (interleukin-2) expression, in 
particular, has been used to characterize anergic T cells20. Deletion occurs by apoptosis. Cell 
intrinsic molecular pathways separately regulate anergy and apoptosis, but extracellular 
triggers can induce both processes. Different T cell subsets derived from within and outside 
the thymus contribute to peripheral immune suppression21. 
TOLERANCE AND THE THYMUS 
The thymus regulates immune activation and tolerance via the T cells it generates and 
releases into the periphery. Understanding the importance of thymus function is a relatively 
recent discovery in the field of immunology that did not happen until the early 1960s18. 
In the last fifty years, the contribution of the thymus to immune tolerance and 
regulation has been extensively investigated. The thymus selects a diverse pool of T cells that 
are capable of mounting an immune response to foreign antigen but selectively deletes or 
suppresses most autoreactive T cells. Because some autoreactive T cells escape from the 
thymus, peripheral regulation mechanisms are needed to protect the body from immune 
mediated destruction. One way in which the thymus compensates for generating autoreactive 
T cells is by generating natural regulatory T cells (nTregs), which have dominant 
immunosuppressive abilities. 
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DISCOVERING THYMUS FUNCTION 
The thymus is essential for selection of a T cell repertoire that can defend against 
diverse pathogens and is tolerant to self. However, prior to Jacques Miller’s neonatal 
thymectomy experiments in the 1960s, the common perspective amongst most 
immunologists was that the thymus was an evolutionary redundancy that served as a 
lymphocyte graveyard in humans and other mammals18,22. 
The belief that the thymus did not serve a critical function was rooted in observations 
of adult mice. First, adult thymectomy in mice had no noticeable effect on immune function. 
Second, while immunologists agreed that immune cells were present in the thymus, the organ 
lacked germinal centers, which indicated the presence of an immune response in other 
lymphoid organs. Third, adoptive transfer of thymic lymphocytes did not transfer immune 
responsiveness to antigen. Finally, the lymphocytes that possessed immune response 
initiating activity were found in circulation but never entered the thymus. Together, these 
data were taken to mean that the thymus was unnecessary for immunity22. 
MILLER’S THYMECTOMY EXPERIMENTS 
Miller’s thymectomy experiments in newborn mice clearly demonstrated that the 
thymus was a necessary immune system attribute and laid the foundation for future 
investigation into thymic function. First, he showed that neonatal thymectomy impaired the 
immune response against infection and permitted allogeneic skin grafts, which would 
otherwise be rejected. Next, he showed that thymic grafts could rescue immune function in 
thymectomized mice. He tested syngeneic and allogeneic thymic grafts. Interestingly, 
recipients of allogeneic thymus were tolerant to donor histocompatibility antigens, indicating 
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that some kind of tolerance-inducing selection process might be happening in the thymus. 
Other groups generated similar data sets around the same time. The significance of the 
thymus to establishing proper immune function early in life became widely accepted18. 
Thus, Miller’s neonatal thymectomy experiments established that the thymus had an 
immunologic function. The next step was to figure out what the thymus-derived cells did in 
relation to immune cells from other anatomical compartments. 
EXPERIMENTAL FOUNDATIONS FOR B CELL AND T CELL FUNCTION 
The complementary, dual functions of lymphoid cells were first observed in adoptive 
transfer experiments performed by Henry Claman and colleagues. Claman transferred 
different combinations of lymphoid organ preparations plus immunostimulatory sheep red 
blood cells (SRBCs) into irradiated recipients. Antibody production could be assayed by the 
hemolytic plaque-forming assay. If an in vivo antibody response against transferred SRBCs 
formed, then preparations of splenocytes plus complement would cause plaque formation on 
sheep blood agar plates10. In Claman’s system, transferred spleen cells alone generated an 
antibody response, but neither bone marrow nor thymus alone could. When the bone marrow 
and thymus preparations were transferred in combination, a robust antibody response was 
produced. Thus, bone marrow and thymus derived cells synergized to produce an antibody 
response against the SRBCs. While Claman’s system established complementation between 
bone marrow and thymus derived cells, he did not know which lymphoid source produced 
the antibody23. 
Next, Miller and his student, Graham Mitchell, used a complex parental/ allogeneic 
hybrid transfer system to build upon Claman’s findings and establish that antibody producing 
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cells were not thymus derived24. At this point, Miller had already shown that thoracic duct 
preparations shared similar immune reconstitution abilities with thymocytes10. 
To test whether thoracic duct/thymus-derived cells produced antibodies, Miller and 
Mitchell took adult CBA mice, removed the thymus, irradiated them, and protected them 
with CBA bone marrow. Two weeks later, they transplanted mice with SRBCs and thoracic 
duct cells from CBA X C57BL F1 hybrids. They waited a week, harvested splenocytes, and 
selectively depleted different donor cells from the splenocytes by treatment with either α-
CBA or α-C57BL sera. If thoracic duct-derived cells from the CBA X C57BL F1 hybrids 
produced antibody, then α-C57BL sera would block plaque formation. The α-C57BL sera did 
not block plaque formation, but α-CBA did, indicating that the antibody producing cells were 
derived from the bone marrow and not from thoracic duct cells. In a later experiment, Miller 
would find that the thoracic duct preparations were mostly comprised of thymocytes24. 
Further experiments from Miller and others established the dual functions of 
lymphoid cells, whereby bone marrow-derived cells produce antibody and thymus-derived 
cells enhance antibody production by providing help, hence the term T helper cells (TH)25. 
Eventually, the terms T cell and B cell came to be used to describe thymic-derived and bone 
marrow-derived lymphocytes, respectively. However, it is worth noting that the term B cell 
was originally used to describe cells from the bursa of Fabricius, an antibody-cell-producing 
organ in birds that does not have a known analog in mammals10,26. 
THE THYMUS AND ADULT IMMUNITY  
For many years, the thymus was thought to be dispensable for adult immunity. First, 
the thymus involutes with age. Involution does not change the gross thymic size. Instead, 
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adipose tissue expands and takes over the thymopoietic epithelial spaces. In a newborn 
human, ~95% of the thymus is devoted to thymopoiesis; thymopoietic space comprises only 
~10% in seventy year olds. Also, thymectomy, used to remove thymic tumors in myasthenia 
gravis patients, was not associated with subsequent apparent immunodeficiency27. Taken 
together, these pieces of information were interpreted to mean that ongoing thymic 
production was not necessary throughout life. The pool of T cells generated early in life 
would be sufficient to provide immunity and tolerance. Once a diverse pool of T cells was 
released from the thymus, the organ was no longer needed. 
However, Miller had provided data showing that the thymus was needed in adult mice 
around the same time he published the neonatal thymectomy experiments. He hypothesized 
that adult mice might require the thymus for immune recovery after irradiation damage. 
Irradiated, sham thymectomized mice recovered the ability to form an immune response 
against SRBCs. In contrast, thymectomized mice did not recover from irradiation damage. A 
similar immune defect was observed in response to skin grafts. Instead of rejecting allogeneic 
skin grafts, irradiated, thymectomized mice tolerated the grafts many weeks longer than 
immune-competent controls28. 
These data from thymectomized, irradiated mice were accepted, but most people 
thought the system was physiologically irrelevant because so many manipulations had been 
performed. The phenotype Miller observed in his irradiated, thymectomized mice roughly 
parallels symptoms caused by infection with human immunodeficiency virus-1 (HIV-1). The 
wasting symptoms and increased susceptibility to infection in AIDS (acquired 
immunodeficiency syndrome) patients and in the manipulated mice can be attributed to T cell 
defiency18. 
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The thymus, HIV-1 infection, and aging 
Thymic output studies comparing HIV-1 infected patients to non-infected adults led 
to a reevaluation of the dogma that the thymus was dispensable to adult immunity. A pivotal 
study used TCR excision circle (TREC) analysis (see TREC assays below) to make two 
novel observations regarding aging and HIV-1 infection: 
1) Thymic T cell production declines with age, but actually continues until age 80, 
and possibly later29.  
2) HIV-1 infection severely reduces thymic output, but impaired thymus activity can 
be restored by highly active anti-retroviral therapy (HAART)29. 
Definitive evidence for restored thymic function led to the idea that thymus directed 
therapies could benefit HIV-1 infected patients, the elderly and patients receiving cytotoxic 
cancer chemotherapy. These shifts in thinking about the thymus and technological advances 
have contributed to a growing interest in TEC biology and thymic organ development30,31. 
THE THYMUS 
The main goal of the thymus is to produce a diverse population of T cells that can 
protect against a broad range of pathogens, but maintain tolerance to self. Although 
thymocytes are the predominant cell population within the thymus, thymic stromal cells, 
including TECS, are vital to thymocyte survival and differentiation. Nude mice 
(spontaneously deficient in FoxN1) are deficient in T cells because TECs fail to differentiate 
and the thymus organ does not form. Even during the earliest stage of organ development, 
TECs are necessary to recruit hematopoietic precursors to the emerging thymic rudiment. 
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Crosstalk between thymocytes and TECs continues on during development and persists 
throughout life; it is necessary for the viability of both populations32. 
The thymus is divided into two main regions: the outer cortex and the inner medulla. 
The cortico-medullary junction contains blood vessels that allow entrance of thymocyte 
precursors and exit of mature, naïve T cells. The outer region of the cortex is called the 
subcapsular region. The early phases of pre-TCR development and positive selection occur in 
the subcapsular regions and the cortex. Antigen-specific negative selection is thought to 
occur in the medulla32,33. Phagocytic macrophages, dendritic cells (DCs), medullary TECs 
(mTECs) and cortical TECs (cTECs) are all important stromal cell populations that 
contribute to thymocyte selection. 
THYMIC ORGANOGENESIS 
A basic knowledge of embryonic development is helpful to understanding the earliest 
steps of thymic formation and organization. Three principal germ cell layers exist in the 
developing embryo: ectoderm, mesoderm, and endoderm. The endoderm layer divides into 
two tubes, which form the foundations of the digestive tract and the respiratory system. The 
pharynx is a chamber space shared in common by both endodermal structures. It contains 
four morphologically distinguishable pharyngeal pouches34. 
Pre-thymic body plan organization during development 
Appropriate development of the thymus requires a network of transcription factors 
that are expressed within the pharyngeal endoderm prior to thymic rudiment formation. 
These transcription factors include Hoxa3, Six1, Eya1, Pax1, Pax9 and Tbx135,36. They direct 
pharyngeal body plan patterning, which is necessary for development of a number of 
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structures other than the thymus: ear, tonsils, parathyroid, thyroid and lungs34. Deletion of 
any one of these transcription factors results in failure to initiate the thymus and other 
developmental deformities35. 
DiGeorge’s syndrome and Tbx1 
DiGeorge’s syndrome (DGS) is a genetic disease whose etiology is related to defects 
in embryonic pharyngeal patterning36,37. Failure to form a thymus is a defining feature of 
DGS, but the complexities of DGS go beyond thymic deficiency to include cardiac 
complications, parathyroid deficiencies, facial anomalies, and problems with speech and 
hearing. DGS is associated with deletions in chromosome 22 that range in size between 1.5-3 
million base pairs. Twenty-four to thirty different genes are encoded by the chromosomal 
region deleted in DGS38-40. 
Interestingly, one of the earliest gene knockout mice displayed a phenotype very 
similar to that observed in DGS patients. Like DGS patients, Hoxa3 (originally called hox-
1.5) mutants failed to form a thymus or parathyroid, suffered cardiac defects, contained a 
small thyroid, and exhibited facial abnormalities41. The Hoxa3-/- creators acknowledged that 
important chromosomal differences ruled out the possibility that Hoxa3 would be a DGS 
candidate; they proposed that the genetic deficiencies causing DGS could be involved in the 
same development process as Hoxa341. Molecular geneticists have since revealed a DGS 
candidate gene, Tbx1, that is involved in pharyngeal patterning, similar to Hoxa336,42. 
FoxN1 
By comparison to Tbx1 and the other body plan transcription factors mentioned 
above, FoxN1 function is nearly exclusive to the thymus. The skin is the only other organ 
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besides the thymus known to require FoxN1. Hence, the term ‘nude’ was used early on to 
describe the hairless athymic mouse phenotype. Immunologists used nude mice as an 
experimental tool for many years before identifying the FoxN1 gene10,43,44. 
The primordial thymus originates from the third pharyngeal pouch around embryone 
day 10 (E10) and can be marked by FoxN1 expression by E11.2545. FoxN1-deficient mice 
arrest thymic organ development at E11.5, because TEC differentiation fails and the thymic 
anlage can not attract thymocyte precursors46. 
The ‘dual’ origin theory of thymus development 
While the emergence of the thymus anlage from the third pharyngeal structure was 
accepted for the last thirty years, competing theories about the role of the ectodermal layer 
existed until recently35. The ‘dual origin’ view of thymic epithelial development asserted that 
the thymic anlage originated from both ectodermal and endodermal layers6. A critical 
attribute of the ‘dual origin’ theory was that cortical and medullary regions originated from 
ectoderm and endoderm, respectively47. Support for the ‘dual origin’ theory came from 
comparative histological studies between wild type and nude mice. Alternatively, the single 
origin view of thymic development proposed that only the endoderm is necessary and the 
ectoderm cells are expendable (Reviewed in 35,48). 
Single endodermal origin of the thymus 
In the 1970s, Le Douarin’s chick/quail chimera experiments provided functional 
evidence that the endoderm was sufficient for thymus formation, the ‘single origin’ theory of 
thymic development49. The Japanese quail exhibits a unique heterochromatin-staining 
pattern, which allowed for definitive resolution between quail-derived and chick-derived 
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cells in chimeras. Following engraftment of the quail endoderm, the chick thymus contained 
stromal cells from the quail and lymphocytes from the chick49. Thus, while the chick/quail 
chimera studies definitively showed that the entire thymic epithelium emerged from 
endodermal cells, the ‘dual origin’ hypothesis was not dismissed until analogous experiments 
were performed in mice30,50. Thirty years later, Gordon et al50 performed ex vivo lineage 
analysis using a cell tracking dye in mouse thymic lobes. They saw no evidence for 
ectodermal contribution to the thymus organ. Further, E9 ectoderm-free, pharyngeal 
endoderm cells were sufficient to support thymocyte development when transplanted under 
the kidney capsules of nude mice50. Thus, the entire thymic epithelium is now thought to 
derive solely from the endodermal layer and this paradigm shift is apparent in the 2008 
edition of Janeway’s Immunobiology51. 
Bipotent thymic epithelial progenitors 
The endodermal layer contains bipotent TEC progenitor cells (bTEC) that can give 
rise to both medullary and cortical TECs (mTECs and cTECs, respectively). The presence of 
bTECs was determined by tracking the fate of single enhanced yellow fluorescent protein 
(eYFP)-positive endodermal cells in eYFP-negative thymic lobes. eYFPpos cells were present 
in ~30% of the injected lobes and the eYFP signal colocalized with markers for mature 
mTECs and cTECs. Thus, single endodermal bTECs have the capacity to form both mTECs 
and cTECs52. Further studies are needed to more precisely define and locate bTECs within 
total endodermal preparations. 
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Thymic mesenchyme 
In addition to endodermal-derived TECs, thymic mesenchymal cells and migratory 
cells from the neural crest also contribute to thymus formation by releasing epithelial 
morphogenic factors. Manipulation of the thymic mesenchyme in vivo disrupts thymic 
organogenesis and formation of a thymus organ by re-aggregation requires mesenchymal 
fibroblasts in vitro. The entire set of signals emanating from the mesenchyme during thymic 
organogenesis is not entirely clear, but one known mechanism is the fibroblast growth factor 
(FGF) signaling pathway53. TECs express the FGF receptor. FGF7 and FGF10, growth factor 
ligands secreted by thymic mesenchymal cells, promote TEC expansion, even in the absence 
of mesenchymal tissue54. 
To summarize, multiple factors contribute thymic organogeneis. First, appropriate 
pharyngeal body patterning must occur. Then, FoxN1-dependent TEC differentiation initiates 
within endodermal-derived tissue. Signals from the thymic mesenchyme contribute to TEC 
differentiation. Finally, TEC differentiation and maintenance are also dependent upon 
colonizing thymocyte precursors, which will be discussed in the next section. 
T CELL DEVELOPMENT 
Hematopoiesis 
Early lymphoid cell development occurs in central lymphoid organs, the bone marrow 
(BM) and the thymus. The liver serves as a central lymphoid organ for the developing fetus. 
The adaptive immune response develops in peripheral lymphoid organs, which include the 
spleen and lymph nodes. 
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The BM is the major site of hematopoiesis in adults and therefore, serves as the main 
source of new immune cells. Hematopoiesis is the process of blood cell development and 
differentiation. All blood components including white blood cells, red blood cells and 
platelets derive from the same progenitors, hematopoietic stem cells (HSCs). HSCs have self-
renewing capacity and are vitally significant because they can reconstitute the entire 
hematopoietic system55. 
The classic HSC differentiation model proposes that the earliest branching step 
divides the myeloid and lymphoid cell lineages56. The common myeloid progenitor (CMP) 
further differentiates into myeloid-derived immune cells, red blood cells, and platelets. B and 
T cells differentiate from common lymphoid progenitors (CLPs). B cells complete 
development in the BM. The thymus organ is required for T cell development, but 
specialized stromal cells can partially support T cell development in vitro. 
OP9 stromal co-cultures and thymopoiesis research 
The OP9-Delta-Like (DL) stromal cell lines have become a powerful tool allowing 
researchers to dissect mechanisms regulating thymopoiesis. OP9 cells are a stromal cell line 
derived from the BM of op/op mice, which are deficient in macrophage-colony stimulating 
factor (M-CSF). M-CSF is a myeloid cell differentiation factor that inhibits lymphopoiesis 
because of its positive effect on myeloid cell differentiation. OP9 stromal cell monolayers 
support differentiation of B cells and NK cells from embryonic stem cells because they lack 
M-CSF. Addition of M-CSF to OP9/stem cell co-cultures inhibits lymphopoiesis57. However, 
OP9 cells cannot support T cell development without Notch ligand expression. Constitutive 
expression of the Notch-1 ligands Delta-like-1 and -4 (DL1/DL4) confer OP9 cells with the 
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ability to support thymopoiesis58, because Notch signaling is required for T cell lineage 
commitment59. Although OP9DL1/DL4 cells can support T cell commitment, they cannot 
support T cell differentiation past the DP stage. 
THYMOPOIESIS 
Thymopoiesis, the process of T cell development is also referred to as thymocyte 
selection. A series of checkpoints selects a diverse pool of T cells that can fight new 
infections and is mostly devoid of autoreactive cells. The TCR is the principal molecular 
element that confers a high level of antigen recognition diversity to the adaptive immune 
system. The conventional TCR is a multi-component complex comprised of variable α/β- 
subunits and non-variable CD3 subunits. The α/β-chains confer antigen specificity, while the 
CD3 cytoplasmic tails transmit signaling information, leading to T cell activation60. 
Alternatively, TCRs can form from γδ subunits, leading to formation of γδ T cells. γδ T cells 
and NKT cells are innate-like effectors that both differentiate in the thymus. 
ETPs and HSC paradigm revisions 
The differentiation state of the early thymic progenitors (ETPs) that migrate from the 
bloodstream into the thymus has been an open question for some time. Investigators have 
asked whether ETPs were similar to CLPs with B cell potential, or, might ETPs have already 
differentiated towards T-cell lineage commitment?55 Efforts to define ETPs have led to 
controversy concerning the first step in the classic HSC paradigm61. In contrast to the early 
myeloid and lymphoid split proposed by the classic HSC model, support for a common T 
cell/myeloid lineage has come from two separate groups that used complementary assay 
systems62,63. Wada et al.63 performed single cell clonal assays in vivo and in vitro. Bell and 
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Bhandoola62 used the in vitro OP9-DL4 differentiation system and identified markers of TCR 
gene rearrangement within sorted thymic-derived granulocytes. Both groups obtained data 
showing that ETPs retain myeloid potential, but lack B cell potential. These questions of ETP 
potential are relevant to understanding the basic biology of the thymus and the etiology of 
acute myeloid leukemia56. 
Pre-TCR development 
Once an ETP enters the thymus, it is likely to encounter factors that promote T cell 
lineage commitment. The pre-TCR phase of development happens in cells described as 
double negative (DN) because they lack CD4 and CD8 co-receptor expression. During the 
DN phase, progenitors proliferate, commit to the T-cell lineage and rearrange TCR genes. 
DN thymocyte differentiation phases are defined by CD44 and IL-2 receptor-α (IL-
2Rα/CD25) expression. The most immature DN cells are CD44posCD25neg (DN1) and are not 
fully committed to the T cell lineage64. 
One example of TEC dependence on thymocytes comes from mice that express the 
human CD3ε transgene and arrest thymopoiesis at the DN1 stage. As a consequence of DN1 
arrest, immature TECs fail to differentiate into mature cTECs32. 
The transition to DN2 (CD44posCD25pos) is driven by thymus-derived signals. cTECs 
express Notch ligands that are essential for T cell lineage commitment. Delta ligands 
expressed by cTECs bind to Notch receptors on the thymocyte. Ligation of Notch by Delta-
like ligands leads to proteolytic cleavage and release of the Notch intracellular domain 
(NotchIC), thereby allowing nuclear translocation of NotchIC and transcriptional 
reprogramming of the thymocyte64. 
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Also, cTECS secrete IL-7, which is necessary for thymocyte proliferation and 
survival. Genetic deletion of IL-7, the IL-7 receptor, or γc (an IL-7 receptor component) 
arrests thymocyte development. Germline TCRb, TCRg, and TCRd rearrangements initiate 
during DN2, which prepares thymocytes for the first phase of TCR selection64. 
TCRβ selection 
Successful TCRβ rearrangement and production of a signaling-competent pre-TCR is 
a necessary checkpoint called β-selection that occurs at the DN3 (CD44negCD25pos) phase. 
The pre-TCR is a rearranged TCRβ chain paired with the invariant, preTCR-α chain. TCR 
rearrangements depend on RAG (recombination activating genes) enzymes. The TCR 
rearrangement process is stochastic, resulting in 2 out of 3 recombination events that cannot 
produce a TCRβ protein. Cells that do not make productive TCR rearrangements cannot pass 
the β-selection checkpoint. Once formed, the pre-TCR promotes survival and inhibits 
apoptosis by cell autonomous signaling33,65. Knockout of RAG or multiple downstream TCR 
signaling components (Lck, Syk, Lat, and Slp76) arrest thymocytes at the DN3 phase64. 
γδ T cell development 
If TCRg and TCRd rearrangements make a productive TCR, then thymocytes can 
become γδ T cells instead of αβ T cells. TCR-ligand interactions appear to be instructive 
towards the γδ cell fate33. γδ T cells share some functions with innate cells, including 
epidermal maintenance, resistance to certain infections and antigen presentation. Even 
though γδ T cells form a minor population amongst circulating and lymphoid resident T cells, 
they comprise 50% of the T cells found at epithelial surfaces66. 
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TREC assays 
The mechanics of TCR gene rearrangement leads to the production of excised DNA 
circles that remain within the cell even after it has egressed from the thymus. Researchers 
took advantage of a novel PCR-based assay to measure thymic output based on these unused 
pieces of TCR DNA. The intervening pieces of DNA loop out and form circles, called TCR 
excision circles (TRECs). Because TRECs are extrachromosomal, subsequent cell divisions 
dilute the presence of TRECs. Therefore, high TREC levels are associated with recent thymic 
emigrants, while low TREC levels associate with T cells that have undergone multiple 
rounds of cell division. The TREC assay has been used to show progressive thymic 
functional decline during aging and in HIV-1 infected patients29,67. 
DN thymocytes migrate through the cortex 
In addition to proliferating and rearranging TCR genes, DN2/3 cells migrate through 
the cortex away from the cortico-medullary junction towards the outermost subcapsular 
region in response to chemokine signals. Concentrated TGF-β (transforming growth factor-β) 
in the subcapsular region may be responsible for inhibiting cell cycle progression and could 
slow down the transition out of DN332. 
The TCRα loci rearranges following β-selection and the thymocyte transition from 
DN3 to DN4 (CD44negCD25neg). The DN4 cells upregulate CD4 and CD8 to become double 
positive (DP, CD4posCD8pos) cells without requiring any identifiable signal64. 
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THYMOCYTE SELECTION AND TCR AFFINITY 
The latter phase of thymocyte selection seems to depended upon the affinity of 
interactions between the TCR and self peptide-MHC ligands presented on thymic stromal 
cells. Accordingly, if the TCRs interact with self peptide-MHC molecules with moderate 
affinity, then those cells are positively selected to survive. Conversely, high affinity 
interactions between TCRs and self-peptide MHC results in either deletion by negative 
selection or Treg selection, though a bias favors deletion over Treg selection33,68. TCRs that do 
not interact with thymic MHC die by neglect. The thymocyte selection process chooses only 
~3% of the initial pool of DP cells to survive68. 
NKT cell development 
The NKT cell lineage is an alternative cell fate that can be selected if a DP cell TCR 
is stimulated by a thymic lymphoid cell, rather than a thymic stromal cell33. NKTs share 
phenotypic features with both NK and T cells. NKTs are considered innate effectors because 
they can rapidly respond to antigen, leading to production of both pro- and anti-inflammatory 
cytokines69. 
Positive selection and death by neglect 
Positive selection occurs as DP cells migrate through the cortex and interact with 
cTECs. If the TCRs expressed by DP cells do not interact with self peptide-MHC molecules 
on cTECs, then those DP cells do not mature and they die from neglect. Host MHC 
restriction selects T cells in the thymus that will require the same host MHC molecules in the 
periphery in order to recognize antigen and receive appropriate stimulation cues. TCR 
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ligation by self peptide-MHC leads to upregulation of the chemokine receptor CCR7, which 
promotes migration towards medulla, in response to CCL19 and CCL2132,70. 
Negative selection 
Negative selection is the process by which thymocytes with high affinity for self-
peptide-MHC are deleted by apoptosis. It is mediated by BM-derived antigen presenting cells 
(APCs), including DCs and macrophages, and mTECs. mTECs uniquely contribute to self-
tolerance because of their ability to promiscuously express tissue-restricted antigens (TRAs) 
under control of the autoimmune regulator (Aire) transcription factor. Aire is essential to T 
cell tolerance and Aire mutations are associated with APECED (derived from autoimmune 
polyendocrinopathy candidiasis ectodermal dystrophy) disease in humans71. 
CD4 T CELLS IN THE PERIPHERY 
Upon egress from the thymus, naïve CD4pos T cells have a range of eventual fate 
options that are dependent upon cytokine signals received in the lymphoid microenvironment 
during activation. Functionally, conventional CD4pos TH cells have been associated with 
facilitating B cell antibody production, enhancing anti-microbial activity in macrophages, 
recruiting granulocytes, and producing immune suppressive cytokines72. 
In the classic TH1 versus TH2 paradigm, naïve TH cells have two cell fates available 
during the course of activation. TH1 cells promote cell-mediated immunity and are needed for 
intracellular pathogen clearance. TH2 cells promote B-cell antibody production and are 
needed to remove extracellular parasites. Each cell type is associated with an effector 
cytokine profile and with specific nuclear transcription factors that commit cells to either the 
TH1 or the TH2 lineage. Organ specific autoimmune disease was attributed to TH1 
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perturbations; asthma and allergy were caused by TH2 aberrations. Antagonism between TH1 
and TH2 cells has been proposed as a means of immune regulation72. 
The classic TH1/TH2 dichotomy has been exploded in recent years by the 
identification of other TH cell fate options, which will be described in more detail below 
(iTregs and TH17 Cells). 
FROM SUPPRESSOR CELLS TO FOXP3POS TREGS 
Richard Gershon and Kazunari Kondo first described the existence of suppressor T 
cells in the early 1970s73. Gershon and colleagues observed that combining different 
thymocyte populations resulted in decreased DNA synthesis compared to one of the 
populations alone. The experiments were performed in the absence of B cells, so they 
concluded that a T cell to T cell suppressor mechanism could be at play. They proposed that 
a putative population of T cells suppressed the proliferative response of other T cells74. Tregs 
perform the exact same suppressor function first proposed many years before their identity 
could be agreed upon75. 
In 1995, Sakaguchi et al76 described a population of CD4posCD25pos T cells that 
protected multiple tissues from autoimmune destruction. Depletion of CD4posCD25pos cells 
from splenocytes elicited autoimmune disease in multiple organs when transferred into 
syngeneic athymic nude mice. Reconstitution of CD4posCD25pos-depleted-splenocyte 
recipients with CD4posCD25pos cells shortly after transfer protected from autoimmune 
disease76. Thus, the CD4posCD25pos population contained immune suppressive function that 
was more ubiquitous than suppressive function associated with any other T cell surface 
marker combination that had been tested (Reviewed in 73). 
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IPEX patients and scurfy mice 
By 2003, two pieces of evidence established that the Foxp3 transcription factor 
inhibited autoimmunity. A naturally occurring X-linked recessive mutation in the scurfy 
mouse was linked to massive lymphocyte accumulation in multiple organs in affected males. 
Depletion and adoptive transfer experiments established that CD4pos T cells mediated the 
autoimmune pathology in scurfy mice77. Second, IPEX (derived from immunodysregulation, 
polyendocrinopathy, enteropathy X-linked) patients contained mutations in the FOXP3 
gene78-80. 
FOXP3 AND TREGS 
The greatest leap forward for Treg biology came in 2003 when two groups linked the 
development and function of Tregs to Foxp3 in mice. The laboratories of Shimon Sakaguchi 
and Alexander Rudensky independently performed in vitro gene transfer and in vivo adoptive 
transfer experiments to demonstrate that CD4posCD25pos T cells expressed Foxp3 and that 
Foxp3 expression conferred a suppressive phenotype81,82. These experiments suggested that 
Foxp3 was necessary and sufficient to confer Treg properties. The Treg functional phenotype is 
characterized by the ability to suppress effector T cell (Teff) cytokine production and 
proliferation, the inability to produce IL-2 and a hypoproliferative response to antigenic 
stimulation in vitro73,79. Foxp3 expression promotes all aspects of the Treg functional 
phenotype. 
The Treg surface phenotype is associated with constitutive CD25/IL-2Rα expression 
combined with CD4. However, this surface marker signature is not exclusive to Tregs, since 
naïve T cells upregulate CD25/IL-2Rα during activation without acquiring suppressive 
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properties. Additionally, in newborn mice, the thymus produces CD4posCD25pos cells that 
lack Foxp3 expression and are not capable of suppressing responder cells83. Thus, compared 
to CD25/IL-2Rα, Foxp3 expression is a more reliable marker of suppressive T cell function. 
Recent experiments demonstrated that exogenous Foxp3 is not always sufficient to 
confer Treg properties79. Feurer et al84 point out that phenotypic data from Foxp3GFP reporter 
mice and multiple gene array data sets reject the hypothesis that Foxp3 is a master regulator 
of the Treg lineage. Other factors upstream of Foxp3 expression also contribute to the Treg 
phenotype. Feurer and colleagues proposed that Foxp3 might be thought of as a “primus iner 
pares” or oligarchy member84. Still, even if Foxp3 must be demoted, it is still thought to be 
extremely important for Treg development, function, and peripheral maintenance84,85. 
A wealth of investigations into Foxp3pos Treg biology has revealed a wide range of 
proposed suppressive mechanisms and target cells. The long list of Treg targets includes T and 
B lymphocytes, DCs, macrophages, osteoblasts, mast cells, NK cells, and NKT cells. Treg 
suppression in vivo can be contact-dependent and contact-independent. Tregs can induce cell 
cycle arrest and apoptosis by secreting immunosuppressive cytokines (IL-10, TGF-β, and IL-
35), consuming immunostimulatory IL-2, inducing cytolysis, and by expressing negative 
regulators of immune activation on their cell surface75. 
While Tregs play a beneficial role in autoimmunity, allergy, and pregnancy, Tregs are 
detrimental in many tumor microenvironments86,87. Tregs inhibit other immune effectors from 
attacking and clearing cancerous cells88,89. 
In contrast to the poor prognostic trans effects associated with Foxp3pos tumor-
infiltrating T cells88-93, epithelial cell-intrinsic Foxp3 tumor suppressor properties could be 
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beneficial. Foxp3 functions as a breast cancer tumor suppressor gene that represses the 
oncogenes Her2/neu and Skp294,95. More research is needed to dissect the role of Foxp3 in 
heterogeneous tumor microenvironments96. 
Thymic nTregs 
Neonatal thymectomy experiments led to the identification of thymic-derived 
CD4posCD25pos Tregs, which have since been designated natural Tregs (nTregs). nTreg 
development happens in the thymus and seems to be subject to the same antigen receptor 
dependent selection processes that are associated with central tolerance and conventional T 
cell development. nTregs are associated with peripheral tolerance because once they leave the 
thymus, they are essential contributors to antigen-specific immunosuppression. 
The mechanisms regulating Treg selection in the thymus are still unclear, but a few 
requirements have been identified. High affinity interactions between TCRs and self peptide-
MHC class II molecules facilitate Treg selection, but are not sufficient. CD28 co-receptor 
stimulation and IL-2 are also necessary97. Thymic stromal lymphopoietin (TSLP) seems to be 
involved in Treg differentiation, as recombinant TSLP enhanced Foxp3 expression in a TSLP 
receptor-dependent manner in the mouse fetal thymic organ culture (FTOC)83. In humans, 
TSLP production by Hassall’s corpuscles has been linked to Treg selection98. Finally, Foxp3pos 
Tregs are mostly found within the thymic medulla suggesting that, in most cases, CD4 lineage 
commitment precedes Treg selection83,97. Aire-mediated expression of TRAs has been 
proposed as a means of influencing the Treg TCR repertoire, but thus far, supportive evidence 
is lacking99. 
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Regulatory T cell function is not exclusive to thymic-derived nTregs but dominant 
immunosuppressive function is closely associated with Foxp3. Induced Tregs (iTregs) that 
differentiate from naïve T cells outside of the thymus upregulate Foxp3 expression and 
possess suppressor properties. iTregs control inflammation at mucosal surfaces, such as the 
lung and the gut21. 
iTregs and TH17 Cells 
iTregs (also referred to as adaptive Tregs by some authors) and TH17 cells are two CD4 
T cell subsets, whose regulation seems to be partially dependent upon Foxp372. 
Foxp3pos iTregs display suppressive properties that are necessary for controlling oral 
tolerance and inflammation in the gut and lung. Conversion of naïve CD4pos T cells to 
Foxp3-expressing iTregs requires antigen presentation, TGF-β and IL-2. Also, retinoic acid 
can enhance iTreg expansion in vitro. Unlike nTregs, Foxp3 expression is transient in iTregs and 
depends on continual TGF-β presence21,100. 
TH17 cells are marked by production of IL-17 and have proinflammatory properties 
that have been linked to organ specific autoimmunity and protection against microbial 
pathogens. The RORγt (derived from retinoic acid receptor-related orphan receptor γt) 
transcription factor is needed for TH17 differentiation. Like iTregs, TH17 cell differentiation is 
promoted by TGF-β. However, TH17 production requires the proinflammatory IL-6 cytokine 
signal to shut down Foxp3 function. In the absence of IL-6 signals, Foxp3 binds and inhibits 
RORγt function. Foxp3 has a similar effect on RORα-mediated transcription. Thus, the 
decision to become either an inflammatory TH17 cell or a suppressor iTreg depends on the 
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balance between RORγt and Foxp3 nuclear transcription factors, which is influenced by 
cytokines in the extracellular milieu100. 
Foxp3neg  Tregs have also been described, but the ‘lineage’ status of these cells is 
controversial. Type 1 regulatory (TR1) cells exert suppressive effects by producing IL-10 in 
the gut. Clearly IL-10 is needed to restrain inflammation as IL10-/- mice succumb to wasting 
disease and colitis101. However, IL-10 production is associated with multiple T cell subsets, 
so the IL-10 producing cells identified as TR1 are likely not a unique lineage. Rather, IL-10 
production may be a feature shared by different lineages at various times after activation. 
Also, TGF-β producing TH3 cells were described before identification of the Foxp3 gene. 
Reassessment of this population indicates that cells previously designated TH3 cells were 
probably Foxp3pos iTregs72. 
Tregs and apoptosis 
Unique apoptosis response patterns have been observed in Tregs compared to 
CD4posCD25neg cells. However, in some cases Tregs have been described as prone to apoptosis 
and in other cases Tregs were relatively apoptosis-resistant. The discrepancies are related to 
the type of stimulus102-106, the tissue source of isolated Tregs106,107 and the experimental 
environment (in vivo vs in vitro)108,109. One group reported increased mRNA for anti-
apoptotic genes in CD4posCD25pos cells108, while another group reported that Foxp3 
transgenic CD4pos cells have increased RNA for pro-apoptotic genes110. 
Extensive genomic analyses also have not revealed apoptotic regulators to be major 
factors associated with Foxp3 expression or the Treg signature. One exception is gene array 
data from Foxp3GFP reporter mice: anti-apoptotic Bcl-2 was elevated and pro-apoptotic 
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caspase-3 was decreased in Foxp3/GFPposCD25pos cells compared to Foxp3/GFPposCD25neg 
cells. Related apoptotic regulators did not exhibit a similar expression pattern111. Further, 
genome wide profiling studies of Foxp3-dependent genes112 and genes occupied by Foxp3113 
did not reveal an association between apoptotic genes and Foxp3 expression or function. 
Thus, while Tregs seem to exhibit apoptotic responses that are often different from 
conventional CD4 T cells, the underlying mechanism is not clear. The observed differential 
apoptotic responses seem to be regulated by Foxp3-dependent and Foxp3-independent 
factors. 
TCR SIGNAL TRANSDUCTION 
Investigation of Foxp3 function at the molecular level has been shaped by a long 
history of research aimed at uncovering mechanisms regulating T cell activation. Full 
activation of a CD4 T cell requires TCR binding to cognate peptide-MHC class II and 
stimulation of the CD28 co-receptor. These two signals lead to cytoskeletal rearrangements, 
proliferation and transcriptional activation within the T cell. T cell anergy occurs when the 
TCR is stimulated in the absence of CD28 ligation60. 
The conventional αβ TCR is a multi-unit complex expressed on the surface of T cells. 
The αβ receptor molecules are highly variable and confer antigen recognition specificity to 
the T cell. The antigen specific αβ pair lacks signal transmission ability, but nonpolymorphic 
CD3 subunits cluster with the αβ pair and provide signaling capability. The CD3 dimers (γε, 
δε, ζζ) are dependent upon αβ coexpression60. 
Antigen recognition by the αβ receptor triggers a cascade of phosphorylation events 
that emanate from the CD3 cytoplasmic tails. The molecular events that translate αβ antigen 
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binding to CD3 phosphorylation are still unclear. Phosphorylated ITAMs (immunoreceptor 
tyrosine-based activation motifs) within the CD3 tails recruit PTKs (protein tyrosine kinases) 
and signaling adaptor molecules that comprise the proximal TCR signaling complex. The 
multimeric TCR signaling complex activates PLCγ (phospholipase Cγ), which hydrolyzes 
PIP2 (phosphatidylinositol 4,5-bisphosphate) to chemical messengers DAG (diacylglycerol) 
and IP3 (inositol triphosphate). DAG activates PKCθ (protein kinase Cθ) and Ras, which 
leads to AP-1 (activator protein-1) activation60. Proximal TCR complex components and 
PKCθ both contribute to NFκB (nuclear factor kappa-light-chain-enhancer of activated B 
cells) activation114. IP3 activates calcium ion (Ca2+) influx, which leads to the activation of 
NFAT (nuclear factor of activated T cells). The combined presence of AP-1, NFκB, and 
NFAT in the nucleus robustly activates T cell effector cytokine gene transcription60. 
Pharmacological TCR simulators 
Many TCR signaling mechanisms have been uncovered in Jurkat cells. Research has 
been aided by two groups of pharmacological agents: phorbol esters and Ca2+ ionophores. 
Combined application of the phorbol ester, PMA (phorbol 12-myristate 13-acetate), and the 
ionophore, ionomycin (Ion), simulates TCR stimulation by activating downstream signaling 
events. PMA activates PKCθ, a target of DAG. Ion raises intracellular Ca2+ levels60. 
TCR downstream signaling 
Ca2+ release from intracellular and extracellular sources is triggered by IP3. IP3 
receptors cause release of endoplasmic reticulum (ER) Ca2+ stores. STIM (stromal interaction 
molecule) senses ER Ca2+ depletion and subsequently opens CRAC (Ca2+ release activated 
Ca2+) channels in the plasma membrane, thereby initiating extracellular Ca2+ influx. Ca2+ 
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binding to calmodulin enables activation of calcineurin. Calcineurin dephosphorylates 
NFAT, permitting exposure of the NFAT nuclear localization signal (NLS), which directs 
NFAT to the nucleus60. 
NFAT and AP-1 bind to DNA by forming a cooperative complex. NFAT-mediated 
gene expression occurs in response to TCR ligation without the need for simultaneous co-
receptor binding. In contrast, TCR stimulation only partially enhances AP-1 and NFκB 
activity. CD28 ligation is needed for optimal activation of the Ras/MAPK (mitogen-activated 
protein kinase) and IKK (IκB kinase) pathways that will be described next115. 
DAG recruits Ras-GRP (Ras guanyl nucleotide-releasing protein) and PKCθ to the 
plasma membrane. PKCθ phosphorylates Ras-GRP. Active Ras-GRP replaces GDP 
(guanosine diphosphate) on inactive Ras with GTP (guanosine triphosphate), yielding 
activated Ras. Ras then activates Raf, a serine/threonine MAPK enzyme. The MAPK kinase 
cascade leads to activation of Elk, which is the kinase that activates Fos and Jun. Fos/Jun 
dimers form the AP-1 transcription factor60. 
The proximal TCR complex activates the canonical NFκB signaling pathway. Genetic 
studies have shown that multiple TCR-associated PTKs and adaptors are involved. A 
recently identified PKCθ-dependent trimolecular complex seems also to be important. IKK 
gets activated by the CARMA, Bcl10, and MALT-1 (CBM) complex [CARMA, caspase 
recruitment domain (CARD) and membrane-associated guanylate kinase (MAGUK)-
containing scaffold protein; Bcl10, B-cell lymphoma/leukemia 10; MALT-1, mucosa-
associated lymphoid tissue lymphoma translocation protein 1]. Activated IKK 
phosphorylates IκB proteins, which leads to their ubiquitin-mediated degradation and release 
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of sequestered NFκB dimers. Once released, the NFκB subunits translocate from the 
cytoplasm to the nucleus where they activate gene transcription114. 
IL-2 signaling and gene regulation 
While multiple cytokines contribute to T cell effector function, IL-2 is essential to 
immune tolerance and Tregs, similar to anergic T cells, are characterized by IL-2 repression. 
Treg survival requires IL-2116. The IL-2 receptor (IL-2R) is composed of three subunits. The 
IL-2Rα chain (also called CD25) confers high affinity for the IL-2 cytokine. Intermediate 
affinity for IL-2 is associated with IL-2Rβ. IL-2Rβ binds to IL-2 and IL-15. The third 
receptor component, γc, has the lowest IL-2 affinity and is essential for signaling by multiple 
cytokines: IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21117. 
For a long time, investigators puzzled over a perceptible paradox regarding IL-2 
signaling. IL-2 was required to support T cell activation in vitro, suggesting that IL-2 might 
be necessary to form an immune response. However, IL-2 deficient animals effectively 
mounted an immune response against pathogens. Contrary to predictions informed by in vitro 
experiments, IL-2-/- animals succumbed to severe autoimmune disease116,118. 
The identification of Tregs and their dependence on IL-2 resolves some of the prior 
confusion regarding IL-2’s function in vivo. Tregs require IL-2 for survival and constitutively 
express the high affinity IL-2 receptor, but Tregs do not produce IL-2 themselves. Adoptive 
transfer of wild type CD4posCD25pos T cells rescued IL-2Rβ-/- mice from lethal 
autoimmunity, indicating that Treg deficiency caused disease in these mice119. 
IL-2 transcription is a tightly regulated process. CD4pos T cells do not express IL-2 
mRNA in the absence of stimulation, but they quickly turn on IL-2 transcription once 
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stimulated120. The IL-2 promoter contains proximal and distal regulatory elements. 
Approximately 300 base pairs upstream of the IL-2 start site (IL2SS) comprise the minimal, 
proximal IL-2 promoter in mice and humans. Mice contain a distal regulatory element, which 
is responsive to AML-1/RUNX1 (acute myeloid leukemia 1/runt-related transcription factor 
1) and is ~1400 base pairs upstream of the IL2SS121. NFAT, NFκB, AP-1, Oct1 (octamer 
transcription factor 1) and AML-1/RUNX1 all enhance IL-2; Foxp3 represses IL-2117,121. 
FOXP3-MEDIATED GENE TRANSCRIPTION 
Foxp3 is a positive and negative regulator of gene transcription122. Extensive genome 
array analyses have identified hundreds of genes that are both positively and negatively 
regulated by Foxp3111-113,122,123. Mouse Foxp3-transgenic CD4 cells were resistant to T cell 
activation, consistent with the observation that many Foxp3-dependent genes are involved in 
T cell activation and anergy79,113,123. One of the most well characterized molecular effects of 
Foxp3 is IL-2 repression. 
Foxp3-mediated IL-2 repression 
Foxp3-mediated IL-2 repression is associated with direct inhibition of IL-2-enhancing 
transcription factors and by modification of the chromatin structure. Protein to protein 
binding by co-immunoprecipitation has been shown between Foxp3 and transcriptional co-
activators that bind to the IL-2 proximal promoter: NFκB (p65), NFAT124,125, and AP-1 (c-
Jun)126. 
Foxp3 represses IL-2 by binding NFAT and inhibiting NFAT:AP-1-dependent 
activity. In the absence of Foxp3, the NFAT:AP-1 complex activates IL-2 at the ARRE 
(antigen recognition response element), a composite binding site for NFAT:AP-1 complexes. 
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Foxp3 inhibited NFAT’s ability to activate an ARRE reporter and required NFAT in order to 
bind the ARRE DNA sequence125. 
Foxp3 and chromatin modifications 
Foxp3 also regulates gene transcription by recruiting a complex of chromatin 
modifying enzymes and modulating histone acetylation in a promoter sequence specific 
manner127-130. Chromatin consists of DNA tightly wrapped around histone proteins. Eight 
histone units and 146 DNA base pairs comprise a single unit of chromatin131. Histone acetyl 
modifications maintain chromatin in an open, transcriptionally active state. The histone code 
hypothesis predicts that inactive gene promoters will be associated with reduced histone 
acetylation and inaccessible chromatin132. Foxp3 decreases IL-2 promoter acetylation and 
represses IL-2 gene transcription, which is consistent with the histone code hypothesis129,133. 
A number of enzyme groups regulate chromatin structure by the addition or removal 
of acetyl and methyl modifications. Histone deacetylase (HDAC) enzymes remove acetyl 
groups leading to condensed, transcriptionally inactive chromatin131. HDAC activity seems to 
promote DNA methylation by DNA methyltransferases (DMTs), but the enzymatic activities 
have yet to be definitively linked at the molecular level134. DNA methylation is associated 
with transcriptionally inactive chromatin135. Chromatin modifications are reversible. Histone 
acetyltransferase (HAT) enzymes ‘open’ up chromatin structure by adding acetyl groups on 
to histones. In addition, certain histone methylation marks are specific to either open or 
closed chromatin structure. Histone methyl transferases (HMTs) are distinct from DMTs. 
The importance of chromatin structure to transcriptional regulation is highlighted by the 
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observation that HATs, HDACs, and HMTs have been found ‘traveling with’ RNA 
polymerase II131. 
A number of lines of evidence support the hypothesis that Foxp3 modulates gene 
expression by affecting chromatin structure. First, ectopic Foxp3 induces promoter specific 
alterations in chromatin structure in a manner that is consistent with the histone code 
hypothesis. Exogenous Foxp3 repressed IL-2 and reduced histone acetylation at the IL-2 
promoter130,131. Increased histone acetylation was observed at the promoters of genes that are 
upregulated by Foxp3 overexpression in CD4 T cells (GITR, CTLA-4 and CD25)125,129. 
Second, Foxp3 co-immunoprecipitated with HDAC7, HDAC9, and the HAT, TIP60 (HIV-
Tat interacting protein 60). TIP60 enhancement of Foxp3-mediated transcriptional repression 
was dependent upon HAT enzyme function. Maximal repression of IL-2-transcriptional 
activity required Foxp3, TIP60, and HDAC7128. Third, Zheng et al122 reported that many 
chromatin remodeling genes showed up in their genome-wide analysis of Foxp3 target genes. 
Fourth, another recently identified Foxp3-binding partner, Eos, is also associated with 
chromatin remodeling. Eos was required for repression of IL-2 and silencing of Eos in Tregs 
blocked repressive histone modifications within the IL-2 promoter136. Finally, Eos, TIP60, 
and HDAC7 bind to Foxp3’s transcriptional repressor domain128,136. 
FOXP3 DOMAIN FUNCTIONS 
The mechanisms by which Foxp3 mediates its effects have been informed by 
characterizing Foxp3 domains that are required for or associated with specific molecular 
functions. The defined putative structural domains of full length Foxp3 (mouse, amino acids 
(AAs) 1-429, Figure 2.1) include the N-terminal proline rich region (PRR), the zinc finger 
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(ZnF), the leucine zipper (L.Zip), and the forkhead (Fkh) domain. Extensive investigations 
into Foxp3 function have uncovered specific activities associated with particular regions. 
Foxp3 function and nuclear translocation are partially mediated by proteolytic 
cleavage at two proprotein convertase (PC) motifs located near the N- and C-termini. In vitro 
and in vivo assays revealed that Foxp3 PC motif mutations altered Treg suppressive function. 
The first PC motif is located within Foxp3’s first exon, between AAs 48-51; the latter is near 
the end of the C-terminus (AAs 414-417)137,138. 
Truncation analysis by Steven Ziegler’s group identified two transcriptional repressor 
regions within the Foxp3 N-terminus. The first repressor domain spans AA’s 67-132 and 
overlaps with the exon 2-encoded domain (AAs 72-105)79,139. The second repressor domain 
(AAs 135-198) is required for NFAT-mediated transcriptional repression79. 
The region encoded by Foxp3’s second exon (AAs 72-105) binds and inhibits the 
transcriptional activities of RORα and RORγt140,141 A FOXP3 isoform that lacks exon 2 was 
identified in humans, FOXP3Δ2142.  
Histone modifying factors associate with both Foxp3 repressor regions (AAs 67-132, 
AAs 135-198)79. AAs 106-190 are required for binding to HDAC7 and TIP60128; AAs 148-
198 bind Eos, a transcription factor associated with histone modifications in the IL-2 
promoter136. 
AAs 199-223 encode the Foxp3 ZnF domain. No known function is associated with 
the ZnF and it is the only described domain that is not associated with a sequenced IPEX 
mutation139. 
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The L.Zip domain (241-268) is required for Foxp3 homodimerization and Treg 
suppressive function139,143,144. The IPEX Δ250 mutation is sufficient to block suppressor 
function in vivo and in vitro143. The IPEX mutation Δ251 blocks FOXP3-mediated IL-2 
inhibition144. 
The region between the Foxp3 L.ZIP and the Fkh domain (AAs 278-337) contains 
AML-1/RUNX1 binding activity. Triple point mutations at AA residues 329/330/332 inhibit 
Foxp3:AML-1/RUNX1 binding, block IL-2 repression, and suppressor cell function121. 
The Fkh DNA binding domain is highly conserved amongst all members of the 
forkhead box (Fox) family145. The Foxp3 Fkh domain is required for DNA binding, nuclear 
translocation, cytokine transcription regulation, and NFAT-mediated suppression125,139. The 
Fkh domain contains more IPEX mutations than any other single domain. Our group has 
shown that the Fkh domain is required for NFκB-mediated HIV-1 LTR (long termninal 
repeat, HIV-1 sequence containing promoter activity) enhancement130. 
SIVA: PRO-APOPTOTIC MOLECULE WITH T CELL SIGNALING PROPERTIES 
Our efforts to understand FOXP3 function on the molecular level led to identification 
of a previously unknown FOXP3-binding partner, Siva. Siva is a pro-apoptotic molecule that 
is also involved in T cell signaling. 
Siva was originally identified in a screen for CD27 binding partners and was named 
after the Hindu god of destruction146. Subsequent investigations have revealed multiple Siva 
binding partners that are associated with diverse cellular functions (shown in Table 1.1). In 
addition to binding CD27, Siva interacts with two other members of the tumor necrosis factor 
receptor (TNFR) family, GITR (glucocorticoid-induced TNFR-related protein) and OX40147. 
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Siva has been localized to multiple subcellular compartments (Table 1.2). Using a panel of 
mouse and human tissues, investigators detected abundant Siva mRNA in most tissues 
screened by Northern blot146,148. Two isoforms, Siva-1 and Siva-2, are present in mouse and 
human148,149. 
Siva and T cells 
Although many reports focus on Siva’s pro-apoptotic function, Siva has been 
described as a regulator of T cell signaling. Siva inhibits NFκB activity by blocking IκBα 
degradation, leading to reduced levels of nuclear NFκB150. Another group found that Siva 
associates with TAK1 and TAB1 (TAK1, TGF-β activating kinase and TAB1, TAK1-
binding protein), signaling adaptors that activate both NFκB and AP-1. XIAP (X-linked 
inhibitor of apoptosis) inhibited Siva’s association with TAK1 and TAB1 and promoted 
Siva-mediated AP-1 activation151. 
Siva binds to the cytoplasmic tail of CD27, a member of the TNFR superfamily. 
TNFRs are transmembrane receptors that mediate cell death and survival by binding to 
death-domain (DD) and TRAF (TNF receptor associated factor) adaptors, respectively. DD-
molecules activate apoptosis and TRAFs are generally associated with NFκB- and AP-1-
mediated survival signals152. However, some TNFRs, including CD27, do not contain DDs in 
their cytoplasmic tails. Thus, Siva provides a means by which CD27 has the capacity to 
transmit a pro-apoptotic signal. CD27 promotes survival by activating NFκB and c-Jun via 
TRAF-2153. 
CD27 expression is associated with naïve, effector and memory T cells, but is 
elevated during the effector phase. In vitro, CD27 supports T cell clonal expansion. 
 41 
Systemically, CD27 is associated with formation of anti-viral immunity. CD27 knockout 
mice showed reduced antigen-specific naïve T cell expansion and impaired CD8pos T cell 
memory in response to influenza virus153,154. 
CD27’s ligand is CD70, a member of the TNF family. Structurally, CD70 is related to 
TNFα, but unlike TNFα, CD70 remains anchored to the plasma membrane. CD70 is 
expressed by lamina propria APCs, and activated T and B cells146,155. CD70 transgenic mice 
(CD70), whose B cells constitutively expressed CD70, exhibited immune hyperactivation 
that resembled HIV-1-related immunodeficiency. Naïve T cells were depleted in CD70Tg 
mice due to excessive effector-memory cell conversion. Around age 6-8 months, CD70Tg 
mice died from Pneumocystis carinii infection, a characteristic of T cell deficiency156. 
Further support for CD70-mediated immune activation came from an adoptive transfer model 
of IBD. CD70 blockade suppressed IBD155. In contrast to CD70’s T cell activating role in the 
CD70Tg mice, CD70 on kidney carcinoma cells promoted lymphocyte apoptosis, which was 
associated with Siva expression157. 
Siva protein domain organization 
The authors who first identified Siva defined three domains based on sequence 
homology to other known protein functional domains (Figure 2.1A)146. The amino terminus 
was not classified. The central region was named the DD homology region (DDHR) for its 
similarity to DDs in FADD (Fas-associated protein with death domain) and RIP (receptor 
interacting protein kinase 1). Siva-2 lacks the second exon, which includes most of the 
DDHR148. The Siva C-terminus is enriched with cysteine residues. The authors designated a 
putative B-box and a putative ZnF domain within the Siva C-terminus146. Further, the Siva 
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primary sequence predicts formation of a spherical amphipathic helix (SAH), a tertiary 
structure that segregates hydrophilic and hydrophobic residues to either side of the helix158. 
Specific molecular functions have been associated with all known Siva domains (See Table 
1.3). 
Siva and apoptosis 
Activation of mitochondrial-dependent apoptosis by Siva has been described in T 
lymphocyte159 and breast cancer cell lines158,160-162, but the mechanisms by which Siva 
induces apoptosis may be cell type-dependent. In breast cancer cells, Siva’s SAH domain 
binds Bcl-2 and Bcl-XL and inhibits their protective effects158,160-162. However, the full SAH 
domain is not required to induce apoptosis in T lymphocytes159. The SAH domain spans the 
exon-1/exon-2 junction. Exon-2 is missing from Siva-2, yet Siva-1 and Siva-2 induced 
equivalent levels of caspase-3 activity in T cells. One explanation could be that the exon-1 
portion of the SAH is sufficient to induce caspase-3 activation. However, the Siva C-
terminus, which completely lacks the SAH domain, induced equivalent levels of 
phosphatidyl serine exposure compared to the Siva N-terminus. Thus, in contrast to breast 
cancer cells where the SAH domain is sufficient to induce apoptosis, more than one domain 
of Siva contributes to apoptosis in T cells. Further, since phosphatidyl serine exposure and 
caspase-3 activation are downstream of both the mitochondrial-dependent and -independent 
apoptotic pathways, the Siva truncation experiments leave open the possibility that Siva 
could activate mitochondrial-independent apoptosis in T cells159. More investigations are 
needed to clarify whether Siva does indeed use more than one mechanism to induce 
apoptosis in different cell types.
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Siva	  Binding	  Partner	   Related	  Cellular	  Functions	  and	  Comments	  
CD27	  
The	  CD27	  cytoplasmic	  tail	  binds	  Siva-­‐1	  and	  Siva-­‐2146,148	  
	  
Ligation	  of	  CD27	  by	  CD70	  promotes	  apoptosis	  in	  the	  presence	  of	  Siva	  
overexpression146,159.	  
	  
Binding	  between	  CD27	  and	  Siva	  could	  NOT	  be	  detected	  in	  2	  myeloma	  cell	  lines	  
transfected	  with	  Siva	  or	  in	  a	  CD27pos	  B	  cell	  lymphoma	  line79	  
CVB3	  VP2	  protein	  
Mediates	  apoptotic	  response	  to	  Coxsackievirus	  infection	  in	  myocardial	  
cells163,164	  
ARG	  Tyrosine	  Kinase	  
ARG	  phosphorylation	  of	  Tyr-­‐34	  in	  Siva-­‐1	  &-­‐2	  mediates	  apoptosis	  in	  response	  to	  
oxidative	  stress165	  
GITR,	  OX40	   Siva-­‐1	  binds	  both	  and	  functionally	  interacts	  with	  GITR	  to	  promote	  apoptosis147	  
BCL-­‐XL,	  BCL-­‐2	  
Siva	  promotes	  apoptosis	  by	  binding	  and	  inhibiting	  BCL-­‐XL	  and	  BCL-­‐2.	  Siva	  does	  
not	  bind	  Bax,	  	  a	  pro-­‐apoptotic	  member	  of	  the	  BCL-­‐2	  family158,162	  
Pmp22	  
Peroxisomal	  membrane	  proteins	  regulate	  fatty	  acid	  and	  hydroperoxide	  
metabolism.	  The	  functional	  interaction	  between	  Siva	  and	  Pmp22	  is	  
undefined166	  
HPV-­‐16	  E7	  Protein	  
HPV-­‐16	  E7	  competitively	  blocks	  Siva	  binding	  to	  BCL-­‐XL	  and	  blocks	  the	  pro-­‐
apoptotic	  function	  of	  Siva	  in	  response	  to	  UV	  radiation167	  
CD4	   Siva	  enhanced	  HIV-­‐1	  envelope-­‐induced	  apoptosis168	  
Pyrin	   Pyrin	  blocks	  the	  pro-­‐apoptotic	  effect	  of	  Siva	  in	  response	  to	  oxidative	  stress149	  
LPA2,	  S1P4	   LPA2	  degrades	  Siva	  in	  the	  presence	  of	  growth	  factors
169,170	  
SLIMMER	   SLIMMER,	  a	  muscle	  protein,	  inhibits	  Siva-­‐mediated	  apoptosis171	  
Telethonin	  
Like	  SLIMMER,	  Telethonin	  is	  a	  muscle	  cytoskeletal	  protein	  that	  localizes	  to	  
sarcomere	  Z-­‐discs.	  The	  functional	  interaction	  between	  Siva	  and	  telethonin	  is	  
undefined172.	  
XIAP	   Anti-­‐apoptotic	  XIAP	  inhibited	  Siva	  by	  proteasomal	  degradation151	  
 
Table 1.1: Siva interacting partners and associated functions 
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Siva	  Sub-­‐Cellular	  Localization	   Cell	  Line	  or	  Tissue	  &	  Comment	  
Plasma	  membrane	  association	  during	  neuronal	  
apoptosis	  for	  endogenous	  Siva	  
γ-­‐irradiated	  whole	  brain	  was	  submitted	  to	  
subcellular	  fractionation173	  
Cytoplasmic	  &	  Mitochondrial	  
In	  transfected	  HeLa	  cells,	  Siva	  co-­‐localized	  with	  
mitotracker158	  
Translocation	  to	  the	  mitochondria	  in	  response	  to	  
DNA	  damage	  agent	  
HCT116	  colorectal	  carcinoma	  cells	  were	  treated	  
with	  cisplatin160	  
Predominantly	  nuclear	  in	  the	  absence	  of	  LPA2	  
The	  presence	  of	  LPA2	  or	  SIP4	  recruited	  Siva	  to	  the	  
cytosol	  and	  plasma	  membrane	  
NIH3T3	  fibroblasts	  were	  grown	  in	  serum	  free	  
condidtions169,170	  
Cytoplasmic	  &	  nuclear	  in	  undifferentiated	  
myoblasts	  
Cytoplasmic	  in	  differentiated	  myotubes	  
Z-­‐line	  localization	  in	  mature	  muscle	  cells	  
Skeletal	  muscle	  cells171	  
Nuclear	  colocalization	  with	  p53	  
H1299	  lung	  cancer	  cells	  and	  A549	  pulmonary	  
epithelial	  cells174	  
Nuclear	  (diffuse	  staining	  becoming	  punctate	  by	  
24-­‐hours	  post	  transfection)	  
Human	  Peripheral	  Blood	  Acute	  Lympohcytic	  
Leukemia	  (HPB-­‐ALL)	  T	  cells159	  
Siva-­‐1	  formed	  distinct	  nuclear	  aggregates	  in	  the	  
presence	  of	  Pyrin	  
Siva-­‐2	  displayed	  nuclear	  and	  cytoplasmic	  
distribution	  in	  the	  presence	  of	  Pyrin	  
Cos-­‐7	  cells149	  
 
Table 1.2: Siva sub-cellular localization 
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Siva	  Domain	  
AA	  
Position	  
Function	  
N-­‐terminus	   1-­‐47	  
	  
Is	  sufficient	  to	  induce	  apoptosis	  in	  HPB-­‐ALL	  T	  cells;	  Mediates	  nuclear	  
translocation159	  
	  
Needed	  for	  binding	  to	  anti-­‐apoptotic	  HPV-­‐E16	  protein167	  
	  
Binds	  to	  CD27	  and	  likely	  mediates	  binding	  to	  GITR	  and	  OX40,	  since	  these	  
three	  TNFRs	  share	  a	  homologous	  motif	  associated	  with	  Siva	  
binding147,166	  
	  
Binds	  peroxisomal	  membrane	  protein-­‐22	  (PMP22)166	  
	  
N-­‐terminal	  
Tyrosine	  
Tyr-­‐34	  
	  
Mediates	  apoptotic	  response	  to	  oxidative	  stress	  in	  collaboration	  with	  
ARG	  tyrosine	  kinase165	  
	  
SAH	   36-­‐55	  
	  
Necessary	  and	  sufficient	  to	  promote	  apoptosis	  in	  breast	  cancer	  cell	  lines	  
by	  binding	  and	  inhibiting	  BCL-­‐XL	  &	  BCL-­‐2
158,161,162	  
	  
Exon	  2	  
Domain	  
40-­‐103	  
	  
Mediates	  homooligimerization	  of	  Siva-­‐1,	  which	  may	  be	  required	  for	  
Siva-­‐1	  to	  inhibit	  p53	  stability174	  
	  
Inhibits	  binding	  to	  Pyrin149	  
	  
Binds	  1	  zinc	  ion166	  
	  
DDHR	   48-­‐121	  
	  
Is	  NOT	  sufficient	  to	  induce	  apoptosis	  in	  HPB-­‐ALL	  T	  cells159	  
	  
Binds	  the	  VP2	  protein	  from	  the	  virulent	  Coxsackievirus	  B3	  strain	  (AAs	  
114-­‐122)164	  
	  
C-­‐terminus	   114-­‐175	  
	  
Is	  sufficient	  to	  induce	  apoptosis	  in	  HPB-­‐ALL	  T	  cells159	  
	  
Binds	  2	  zinc	  Ions166	  
	  
Binds	  LPA	  Receptor-­‐2	  cytoplasmic	  tail169	  
Binds	  CD4	  cytoplasmic	  tail168	  
Binds	  muscle	  sarcomere	  Telethonin172	  
	  
Dispensable	  for	  binding	  XIAP151	  
	  
 
Table 1.3: Siva functional domains 
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CHAPTER TWO 
REGULATION OF T CELL ACTIVATION BY SIVA AND FOXP3 
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ABSTRACT 
Severe autoinflammatory diseases are associated with mutations in the Foxp3 locus in 
both mice and humans. Foxp3 is required for the development, function, and maintenance of 
regulatory T cells (Tregs), a subset of CD4 cells that suppress T cell activation and 
inflammatory processes. Here we show an interaction between FOXP3 and Siva, a previously 
unknown FOXP3 binding partner. Siva is a pro-apoptotic molecule that is expressed across a 
range of tissues, including CD4posFOXP3pos T cells. We have mapped the FOXP3-binding 
domain to Siva’s C-terminus. A central region of FOXP3 contains Siva-binding activity. We 
show that Siva represses IL-2, a cytokine involved in T cell activation and critical to immune 
tolerance. We observed that the repressive effect of FOXP3 on IL-2 transcriptional activity is 
enhanced by Siva knockdown and diminished by Siva overexpression. Siva’s repressive 
effect on IL-2 expression appears to be mediated by inhibition of NFκB. Siva overexpression 
did not affect NFAT or AP-1 transactivation potential in activated cells. Finally, we showed 
that FOXP3 moderately enhanced Jurkat T cell apoptosis in unstimulated cells, but protected 
Jurkat T cells from apoptosis induced by stimulation with PMA and Ionomycin. In summary, 
the data support the assertion that both FOXP3 and Siva function as negative regulators of T 
cell activation. 
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INTRODUCTION 
The transcription factor Foxp3 is essential for immune system regulation due to its 
role in the development and function of regulatory T cells (Tregs)1,2. The dramatic 
autoimmune phenotype in both mice and humans caused by mutated Foxp3 led to its initial 
identification2,3. In the absence of Foxp3, lethal autoimmunity ensues. Sequencing the 
FOXP3 genes from IPEX (Immune polyendocrinopathy, enteropathy, X-linked) patients 
revealed function ablating mutations throughout domains critical for FOXP3 function4,5. The 
scurfy mouse is an autoimmune mutant that has a spontaneous truncation mutation in Foxp3. 
In addition to its well-studied role in Tregs, an emerging body of work has revealed Foxp3 to 
be a tumor suppressor in breast cancer6,7. Foxp3 activates and suppresses a broad range of 
genes, but the mechanisms by which this happens are not well understood8-10. By 
understanding the relationship between FOXP3 and its binding partners, we hope to 
illuminate how FOXP3 operates as a powerful regulator of immune activation. 
Already, Foxp3 is reported to reside in a supramolecular complex11 and a number of 
specific interactions have been identified12. Co-immunoprecipitation (Co-IP) demonstrated 
binding between Foxp3 and the following partners: NFκB p6513, TIP60, HDAC7, HDAC914, 
FoxP111, AML-1/RUNX115, AP-1 family member, cJUN16, RORα17, RORγt18,19, and Eos20. 
Also, Foxp3 homo-oligomerizes11,21. Wu el al22 demonstrated that Foxp3 inhibits the 
transcriptional enhancing effects of NFAT and AP-1 by disrupting their interaction. 
Regulation of IL-2 gene expression is critical to immune tolerance, Treg development 
and function23,24. Foxp3 inhibits IL-2 production in Tregs and confers trans IL-2 suppressive 
function25. Even before Tregs and Foxp3 became inextricably coupled, researchers 
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investigated the effect of Foxp3 on IL-2 transcription26. While IL-2 is not the sole target of 
Foxp39, coordinated investigations into molecular interactions localized to the IL-2 promoter 
have been a successful strategy thus far, towards understanding Foxp3’s function as a 
transcriptional regulator. 
Here we report a previously unidentified FOXP3 binding partner, Siva. The novel 
interaction was exposed in a yeast two-hybrid screen for FOXP3 binding partners. We were 
interested in Siva for its known cell death promoting properties27,28. The possibility of a pro-
apoptotic molecule that might confer Treg properties was intriguing. Also, Siva binds tumor 
necrosis factor receptor (TNFR) family members associated with (but not exclusive to) the 
Treg surface phenotype: GITR (glucocorticoid-induced TNFR-related protein), CD27, and 
OX4029-33. GITR is highly expressed on Tregs and attributes suppressive properties under 
certain conditions34,35. Siva and GITR functionally interacted to exacerbate apoptosis in a 
transient transfection system29. Thus, we investigated Siva because of its pro-apoptotic 
properties and its ability to bind TNFR family members that are associated with the Treg 
surface phenotype. 
Our data shows a physical interaction between FOXP3 and Siva protein expressed in 
293T cells. We mapped the FOXP3-interacting domain to the C-terminus of Siva. The 
central portion of FOXP3 (amino acids (AAs) 106-332) contains Siva-binding activity. We 
found that Siva repressed IL-2. Additionally, based on Siva knockdown (KD) and 
overexpression experiments, we observed that the relative repressive effect of FOXP3 on IL2 
gene expression was reduced by the presence of Siva. Therefore, Siva and FOXP3 could 
functionally interact to repress IL-2 gene transcription, but further investigations are needed 
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molecularly linked. The repressive effect of Siva on IL-2 appears to be mediated by NFκB, as 
our data and others show a negative regulatory effect for Siva on NFκB activity36. In 
summary, while the pro-apoptotic effect of Siva has been thoroughly demonstrated and 
documented, this analysis of Siva’s effect on IL-2 contributes evidence for the protein’s role 
in T cell signaling. 
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METHODS AND MATERIALS 
Cell culture and plasmids 
293T cells were grown in DMEM-10% FetalPlex (Gemini). Jurkat cells were grown 
in RPMI 1640-10% fetal bovine serum supplemented with 2 mM L-glutamine, 100 U/ml 
penicillin, and 100 mg/ml streptomycin. When needed, Jurkat cells were selected in 1 µg/ml 
puromycin (puro). Puro selection took 3-10 days, depending on transduction efficiency. Puro 
selection was judged to be complete once cellular debris events measured by Gauva 
EasyCyte reached less than 10%. Unless otherwise stated, all tissue culture reagents were 
purchased from Invitrogen. 
Myc/FOXP3 full length and all derivative truncation mutants were expressed in 
pCDNA3.1 and made as previously described10. 
The human Siva-1 cDNA was purchased from ATCC. By PCR subcloning, we 
transferred Siva-1 from pCMV-SPORT6 into pEGFP-C1 to generate an enhanced green 
fluorescent protein(EGFP)/Siva-1 fusion construct. All Siva truncation mutants were derived 
from pEGFP/Siva-1 by PCR subcloning. Splice overlap extension was used to generate Siva-
2 and ΔBbox mutants37. Siva-1 was subcloned into the retroviral vector pHSPG under control 
of the MSCV promoter38. 
A panel of five pLKO lentiviral (LV) vectors expressing short hairpin targets against 
Siva was purchased and tested for knockdown efficiency (Open Biosystems). Targets were 
named based on the last 3 digits of the manufacturer’s clone ID. pLKO contains a puro 
selection cassette and the U6 promoter controls hairpin expression. pLKO-shEGFP and 
pLL5.0-NS served as a negative controls in designated experiments. The IL-2-luciferase and 
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NFAT-luciferase reporter plasmids were gifts from Dr. Gerald Crabtree. Dr. Albert Baldwin 
provided pMHC-3x-κB-Luc. 
Yeast two hybrid screen 
A human thymus cDNA library was screened for FOXP3 binding partners. The bait 
plasmid contained the full length FOXP3 sequence in-frame with the Gal4 DNA binding 
domain (BD). The prey plasmids contained cDNA clones from the human thymus library 
adjacent to the Gal4 activation domain (AD). cDNA clones were amplified using random 
primers and oligo dT primers to generate partial and full-length cDNA clones, respectively. 
Interaction between the DNA-BD and AD permits transcription of reporters for histidine 
(His), adenine (Ade), and β-galactosidase (β-gal) synthesis. His-/Ade- dropout media and 
blue/white screening for β-gal activity permitted selection of clones containing FOXP3 
interacting partners. Another level of selection criteria was provided by increasing doses of 
the His inhibitor, 3AT. 
293T transfections, co-IPs, and antibodies 
293T cells were co-transfected with Effectene according to the manufacturer’s 
protocol (Qiagen). 4 µg total plasmid DNA was added to sub-confluent cells in 10-cm dishes. 
At 48-hours post-transfection, lysates were harvested in PBS, washed once and stored at -
20°. Cell pellets were lysed in modified RIPA (Tris-HCl, pH 7.35, 50 mM; NaCl, 150 mM; 
EDTA, 1 mM; NP-40 1%; NaDeoxycholate 0.25%) supplemented with Complete EDTA-free 
Protease Inhibitor (PI, Roche), PMSF (100 mM), and Sodium Flouride (NaF, 50 mM). 
Immunoprecipitations (IPs) were performed in ~1 ml total volume PBS (supplemented with 
PI, PMSF and NaF): 500 µg protein lysate and 40 µl mouse anti-Myc 9E10 hybridoma 
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supernatant (kindly provided by Dr. Yue Xiong) were added to PBS. The protein lysate 
comprised 5-10% of the IP volume. IPs were incubated overnight at 4° on a rotator; Inputs 
were mixed with SDS loading dye and stored at 4°. A 1:1 mixture of Immobilized Protein A 
(Invitrogen) and Protein G Agarose (ThermoScientific) beads was prepared and washed three 
times with PBS. 40 µl of bead mixture were added to each IP. IPs with beads were incubated 
2-4 hours at 4° on a rotator. Beads were washed four times with cold PBS (no supplements). 
Washed beads were resuspended in 20 µl SDS loading dye and heated to boiling in a 95° 
sand bath (~10 minutes). Boiled samples were run on 10% NuPage minigels according to the 
manufacturer’s instructions (Invitrogen). Following transfer, PVDF membranes were blocked 
with PBS-Tween 0.2%, 5% milk, which was used for all subsequent steps. Membranes were 
incubated with mouse α-GFP (Clontech, Living Colors A.v. Monoclonal Antibody (JL-8), 
100 ng/ml) to detect immunoprecitation of EGFP/Siva fusion constructs. Membranes were 
stripped and reprobed with rabbit α-Myc sera (Also, provided by Dr. Yue Xiong). 
Primary cell culture and stimulation 
We isolated CD4posT cells from PBMCs by negative selection with magnetic beads. 
Subsequently, we sorted CD4pos T cells by positive selection for CD25 expression. 
Immediately following isolation, half of the freshly isolated cells were washed and set aside 
for mRNA isolation. The other cells were treated with anti-CD3 and anti-CD28 for 24-hours, 
prior to colleting pellets and storing them in Qiagen RLT buffer at -80° in preparation for 
mRNA isolation. 
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Standard RT-PCR and quantitative PCR 
The Qiagen RNeasy isolation kit was used to isolate mRNA from frozen cell pellets 
preserved at -80° in Qiagen RLT buffer containing β-mercaptoethanol. Reverse transcription 
reactions were performed with random primers and M-MLV reverse transcriptase in the 
presence of RNase inhibitor. Quantitative Taq-Man PCR was performed using primers from 
Applied Biosystesms. The following primer sequences were used in semi-quantitative RT 
PCRs:  
Siva For, 5’- TACAGCTCAAGGTCCGCGTGAGC-3’, 
Siva Rev, 5’-TCACTGCAGTCCACGAGGCCACA-3’, 
β-actin For, 5’- TCACCCACACTGTGCCCATCTACGA-3’, 
β-actin Rev, 5’- CAGCGGAACCGCTCATTGCCAATGG-3’ 
BioGPS data analysis 
Siva expression data for mouse T cell subsets was obtained from the GeneAtlas 
MOE430, gcrma39 micro-array profile through the public access gene portal, BioGPS40. 
Arrays were probed with RNA isolated from a broad spectrum of tissues and cell lineages. 
Four reporters are associated with the mouse Siva gene sequence. The 1433680_x_at and 
1418377_a_at reporters were excluded because of extremely weak spot intensity compared to 
the 1452020_a_at and 1426323_x_at reporters. Spot intensity values were normalized against 
CD4pos T cells so that data from spots with different re-activities could be subjected to 
statistical analysis. 
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Immunofluorescence 
U2OS were plated onto chamber slides one day before being transfected with 
plasmids expressing Myc/FOXP3 and pEGFP/Siva-1, or appropriate vector controls. At 48-
hours post-transfection, the media was removed. Cells were fixed and stained with either 
Rhodamine conjugated-IgG isotype or Rhodamine anti-Myc. 
Retrovirus production and transduction  
The calcium phosphate method was used to transfect 293T cells with pHSPG, VSV-
G, and gag/pol plasmids41. Retroviral (RV) supernatants (SN) were collected at 48 and 72 
hours and titered on Jurkat cells by spinoculation, as has been described38. Efficiency of 
infectivity was determined based on %GFP expression using a Gauva EasyCyte flow 
cytometer. For subsequent experiments, the %-infected was used to calculate the volume of 
RV SN needed to obtain 99% transduction efficiency for a fixed cell number. For all 
experiments reported here, the transduction efficiency was greater than 94%. Dual 
transductions with pHSPG-Siva and pHSPG-FOXP3 RV were performed as follows. A fixed 
number of cells was transduced with either pHSPG or pHSPG-Siva on day 0. Two days later, 
high transduction efficiency was confirmed, the cells were counted and equal cell numbers 
were distributed and mixed with RV for either pHSPG or pHSPG-FOXP3. Since both sets of 
RV use GFP to mark transduction efficiency, GFPneg Jurkat cells were transduced in parallel 
to control for transduction efficiency. 
IL-2 ELISA 
To evaluate endogenous IL-2, transduced Jurkat T cells were distributed in 96-well 
plates at a concentration of 2x105 cells/well. Cells were activated with phorbol 12-myristate 
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13-acetetate (PMA, 25 ng/ml) and Ionomycin (1 µM). At the end of ~18 hours, cell viability 
was evaluated on a Gauva EasyCyte. Plates were spun down and supernatants were collected 
and stored at -20°. IL-2 concentrations were determined with a BD OptEIA™ Mouse IL-2 
ELISA kit. 
Jurkat transfections and luciferase reporter assays  
In order to perform luciferase assays, Jurkat cells were transfected by electroporation 
in cytomix buffer42. Jurkat cells were harvested, counted and redistributed to yield 5x106 
cells/transfection. Cells were washed once in PBS before being suspended in cytomix buffer 
supplemented with 2 mM ATP at time of use (300 µl buffer/transfection). While cells were 
being washed, plasmid DNA was prepared: 1 µg reporter plasmid (see Plasmids above) was 
mixed with differing amounts of plasmid expressing genes of interest or the vector control 
(10 µg DNA total). Cells in cytomix buffer were mixed with DNA mixtures and transferred 
to cuvettes on ice (Biorad Gene Pulser Cuvette, 0.4 cm). A Biorad Gene Pulser Xcell was 
used to electroporate cells at 300V, 500µF, and infinite resistance. Immediately following 
electroporation of all samples, the shocked cells were diluted in pre-warmed culture media 
(RPMI 10%FBS described above). Cells were cultured in 6-well plates. After resting for 12-
24 hours, cells were distributed into 96-well plates and activated with PMA, 25 ng/ml and 
ionomycin, 1 µM. Duration of activation ranged from 6-12 hours. At the assay endpoint, 20 
µl/well was removed to measure viability and transfection efficieny on Gauva EasyCyte mini 
flow cytometer. Plates were spun and cells were washed once with PBS to remove growth 
media. Cells were lysed in 45 µl 1X Promega Reporter Lysis Buffer and frozen at -80°. 
Plates were read on a Veritas Microplate Luminometer according to the manufacturer’s 
instructions. 
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Statistical analysis 
A two-tailed Student’s t-test was used to evaluate statistical difference between 
experimental treatments and a p-value<0.05 was set as the cutoff for statistically significant 
difference. 
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RESULTS 
Siva physically interacts with FOXP3 
A yeast two-hybrid screen for FOXP3-binding partners was performed with a human 
thymus cDNA library. Six full-length clones for Siva-1 were identified in the screen. We 
chose Siva-1 for further investigation for two reasons. First, Siva regulates T cell apoptosis 
and, second, because Siva associates with TNFR family members that might contribute to 
Treg function: CD27, GITR, and OX4029-33. 
After confirming the interaction in yeast, we tested whether FOXP3 and Siva could 
interact in mammalian cells. Two isoforms, Siva-1 and Siva-2, have been described and their 
protein domain organization is depicted in Fig 2.1A. Siva-2 lacks the second exon, resulting 
in a protein that is missing most of the spherical amphipathic helix (SAH) and death domain 
homology region (DDHR). We performed co-immunoprecipitation (Co-IP) experiments with 
transfected 293T cells. We transfected 293T cells with expression plasmids for EGFP-tagged 
Siva isoforms and Myc-tagged FOXP3, or the appropriate vector control. Myc/FOXP3 was 
immunoprecipitated (IP’ed) with a mouse anti-Myc hybridoma supernatant, 9E10. As shown 
in Figure 2.1B, by western blotting (WB) with antibody against GFP, we detected co-IP of 
Siva-1 and Siva-2 in the presence of Myc/FOXP3, but not in its absence. EGFP alone did not 
co-IP with FOXP3 (Data not shown). Thus both Siva-1 and Siva-2 specifically interact with 
FOXP3. 
Siva is preferentially expressed in CD4 posCD25pos 
Next, we investigated Siva expression in human CD4pos T cells under different 
stimulation conditions. We measured Siva expression by RT-PCR in CD4posCD25neg and 
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CD4posCD25pos T cells. Further, we activated some of the isolated cells for 24-hours. As 
shown in Figure 2.2A, Siva mRNA levels were ~30-fold higher in freshly isolated CD25pos 
cells compared to CD25neg CD4 T cells. The data supports the possibility that human Tregs 
may be enriched for Siva compared to naïve CD4pos T cells. While freshly isolated naïve 
CD4posCD25neg cells expressed less Siva compared to CD4posCD25pos T cells, activation with 
α-CD3 and α-CD28 induced Siva mRNA expression. 
To compare Siva expression in mouse T cell subsets, we took advantage of the public 
gene atlas microarray data from BioGPS39,40. Based on the microarray data for mouse CD4pos 
T cells and CD4posFoxp3pos, Siva expression is slightly increased in the Foxp3pos population 
(Figure 2.2B). 
Siva and FOXP3 co-localize in the nucleus  
Observations in Foxp3GFP mice and in transiently transfected cells suggest 
constitutive nuclear localization of Foxp333,43. In contrast, western blot analysis of nuclear 
and cytoplasmic extracts indicated a minor Foxp3 presence in the cytoplasm44. Siva’s 
localization pattern seems to be dependant on the cell type, the presence or absence of certain 
binding partners, and the differentiation state of the cell (Summarized in Table 1.2)45-52. 
In order to examine whether Siva and FOXP3 would colocalize to similar cellular 
compartments, we stained U2OS cells transfected with EGFP/Siva and Myc/FOXP3 (Figure 
2.3). The majority of cells coexpressing both proteins showed diffuse staining throughout the 
nucleus. Also, a small fraction of Siva expressing cells showed a punctate staining pattern 
that was present in the absence of FOXP3; FOXP3 did not show punctate distribution in the 
absence of Siva. 
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Siva-binding activity is contained within FOXP3’s central region 
Major domains of the FOXP3 protein are associated with specific functional activities 
and binding partners (Figure 2.4)12. The Foxp3 N-terminus is required for NFAT-mediated 
repression of IL-222 and is involved in binding to the RORγt and RORα transcription 
factors19. The leucine zipper (L.zip) domain mediates homo-dimerization of Foxp3, which 
contributes to Treg suppressive function11,21. The C-terminal Foxp3 forkhead (Fkh) domain is 
required for DNA binding and nuclear localization26. A short stretch of amino acids between 
the zinc finger (ZnF) and the Fkh domain is involved in AML-1/RUNX1 binding and is 
involved in IL-2 repression15. 
We used Myc/FOXP3 truncation mutants to characterize the region involved in 
binding to Siva by co-IP in 293T cells (summarized in Figure 2.4A). Mutants lacking the Fkh 
domain (ΔFkh) or the N-terminus (Δ1-71; Δ1-105) bound to Siva with similar efficiency and 
the Fkh domain alone failed to pull down Siva (Figure 2.4B). Thus, the Siva-binding capacity 
of FOXP3 is located within the central region that spans the leucine zipper, zinc finger and 
AML1/RUNX1-binding domains (AAs 106-334). 
The Siva C-terminus is sufficient for binding to FOXP3 
As shown in Figure 2.5A, we designed Siva truncation mutants fused to EGFP’s C-
terminus to cover major domains that have been previously described and associated with 
functional effects (summarized in Table 1.3). We performed co-IPs to map Siva’s FOXP3-
binding domain. Our analysis definitively showed no interaction between FOXP3 and Siva 
mutants lacking the C-terminus (Figure 2.5 B). In contrast, all mutants containing some 
portion of the cysteine rich Siva C-terminal domain interacted with FOXP3. Given that the 
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Siva C-terminus mutant and the ΔZnF mutant both contain the B box domain and both 
interacted with FOXP3, we hypothesized that the Siva B box domain might be necessary and 
sufficient to bind FOXP3. To test our hypothesis, we sub-cloned new mutants encompassing 
the Siva B box domain and full length Siva lacking the B box domain (ΔB box). Subsequent 
co-IP experiments demonstrated that the Siva B box domain is neither necessary nor 
sufficient to bind FOXP3 (Figure 2.5C). 
Siva negatively regulates IL-2 gene expression 
We next investigated Siva function. In order to evaluate the effect of Siva 
overexpression on endogenous IL-2, we transduced Jurkat T cells with pHSPG-Siva-1 RV. 
Two pHSPG-Siva-1 plasmid clones were evaluated for Siva-1 protein expression, 
transduction efficiency and endogenous IL-2 expression in Jurkat cells (Figure 2.6 A-C). The 
rabbit α-Siva FL-175 antibody detected a prominent band from 293T cell lysates transfected 
with pEGFP/Siva, but not in the control lanes. Overexpression of Siva-1 by retroviral 
transduction repressed endogenous IL-2 by ~40-60% compared to pHSPG vector-transduced 
cells. 
Next, we tested the effect of Siva knockdown (KD) on endogenous IL-2 gene 
expression (Figure 2.6D). Jurkat T cells were transduced with pLKO lentivirus (LV) 
expressing shSiva or shEGFP, as a control shRNA. Siva KD enhanced IL-2 expression by 
five fold compared to the shEGFP control. 
Siva negatively regulates IL-2 promoter activity 
In addition to measuring Siva’s effect on IL-2 protein levels, we tested the effect of 
Siva on IL-2 promoter activity. A minimal enhancer element located 300 base pairs 
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immediately upstream of the IL-2 start site regulates transcription through the binding of 
transcription factors and alterations in the chromatin structure53,54. Distal regulatory elements 
also contribute to IL-2 regulation and the minimal enhancer region is sometimes referred to 
as the proximal promoter. In order to investigate Siva’s effect on IL-2 transcriptional 
activation, we used a reporter plasmid containing the IL-2 proximal promoter driving 
expression of the luciferase enzyme. Overexpression of Siva inhibits IL-2 transcriptional 
activity (Figure 2.7 A) and KD of Siva enhances IL-2 transcription in a dose-dependent 
manner (Figure 2.7 B). 
FOXP3 and Siva repress endogenous IL-2 
In order to test whether FOXP3 and Siva functionally interact to repress endogenous 
IL-2, we expressed FOXP3 and Siva in Jurkat cells by transduction with pHSPG RVs (Figure 
2.8A). As expected, FOXP3 and Siva independently repressed endogenous IL-2 (Figure 
2.8B). The presence of Siva appeared to inhibit the repressive ability of FOXP3, but the 
difference was not statistically significant (Figure 2.8C). We also examined the combined 
effects of Siva KD and exogenous FOXP3 on IL-2 (Figure 2.9). KD of endogenous Siva did 
not significantly enhance the repressive effect of FOXP3 (Figure 2.9C). However, the 
presence of FOXP3 slightly, but significantly impaired the IL-2-enhancing effect of Siva KD 
(Figure 2.9D). 
In summary, we observed a trend whereby FOXP3’s ability to repress IL-2 gene 
expression is inversely correlated with the presence of Siva. Similarly, in Siva-KD cells, 
FOXP3 showed greater activity in suppressing the IL-2 gene. 
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Effect of FOXP3 and Siva overexpression on IL-2 promoter activity 
After exploring the hypothesis that FOXP3 and Siva functionally interact to repress 
endogenous IL-2, we hypothesized that FOXP3 and Siva might functionally interact to 
repress IL-2 transcriptional activity. First, we tested the effect of Siva and FOXP3 
overexpression on transcription of the IL-2 proximal promoter in a Jurkat T cell luciferase 
assay. We transfected Jurkat T cells with the IL-2 reporter plasmid and different 
combinations of pHSPG vector, a fixed amount of pHSPG-Siva and a titrated amount of 
pHSPG-FOXP3. As indicated by the data in Figure 2.10A, both Siva and FOXP3 repress IL-
2 transcriptional activity. The data shown in Figure 2.10A was used to calculate FOXP3 
mediated IL-2 repression in the presence and absence of Siva. In Figure 2.10B, the “vector” 
(dark diamonds) data points were calculated by setting the IL-2 RLU for PG/vector (Figure 
2.10A, first dark bar) as 100% IL-2 luciferase activity; the “Siva” (light squares) data points 
were calculated by setting the IL-2 RLU for PG/Siva (Figure 2.10A, first grey bar) as 100% 
IL-2 luciferase activity. FOXP3’s IL-2 repressive effect is illustrated by the decline in %IL-2 
luciferase activity with increasing doses of FOXP3. At lower doses of FOXP3, Siva’s 
presence inhibits FOXP3’s repressive effect on IL-2 luciferase activity (Figure 2.10B, square 
compared to diamond). However, when both genes are overexpressed at a one-to-one ratio, 
Siva does not alter FOXP3 repression of IL-2 transcription. 
Effect of FOXP3 overexpression and Siva knockdown on IL-2 promoter activity 
As shown above in Figure 2.6D, Jurkat cells express endogenous Siva and 
endogenous Siva KD enhances IL-2 promoter activity. We hypothesized that endogenous 
Siva might affect FOXP3’s IL-2 repressive ability. We tested the effect of combined Siva KD 
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and FOXP3 overexpression on IL-2 promoter-driven luciferase activity (Figure 2.11A). Siva 
KD enhanced the repressive effect of FOXP3 on IL-2 transcriptional activity (Figure 2.11B). 
FOXP3 impaired the IL-2enhancing effect of Siva KD (Figure 2.11C). 
Effects of FOXP3 and Siva on NFκB, NFAT, and AP-1 
IL-2 is regulated by multiple transcription factors and chromatin modifications53,54. 
We tested the effects of Siva and FOXP3 on three major IL-2 transcriptional regulators. 
Consistent with published reports and shown in Figures 2.12 A-C, FOXP3 inhibits NFκB13, 
NFAT13,22, and AP-116 transactivation potential in stimulated Jurkat T cells. Siva repressed 
NFκB, but had no effect on NFAT or AP-1 activity in response to stimulation. Interestingly, 
Siva repressed basal level AP-1 activity in the absence of stimulation (Figure 2.12D). The 
repressive effects of FOXP3 and Siva on NFκB activity parallel the effects of both genes on 
IL-2. 
Effects of FOXP3 and Siva on Jurkat T cell viability 
Next, we hypothesized that FOXP3 might alter the well characterized pro-apoptotic 
effect of Siva. We measured cell viability by 7AAD in Jurkat T cells transduced with both 
pHSPG-Siva and pHSPG-FOXP3 RV (transduction efficiency shown in Figure 2.8A). As 
expected, Siva enhanced Jurkat T cell death in the absence of stimulation (Figure 2.13). In all 
experiments we observed that FOXP3 also marginally enhanced apoptosis in unstimulated 
cells, but this effect was not always statistically significant. FOXP3 did not alter the death 
promoting effect of Siva in the absence of stimulation. 
Jurkat T cell apoptosis is induced by exposure to PMA and ionomycin for ~18 hours. 
Under these PMA/ionomycin treatment conditions, the pro-apoptotic effect of Siva 
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overexpression was small, but statistically significant (Figure 2.14). Interestingly, FOXP3 
protected Jurkats from PMA/ionomycin-induced apoptosis. Fold-change analysis of cell 
death measurements did not indicate an antagonistic effect between Siva and FOXP3 (data 
not shown). Finally, the stimulation-dependent effect of FOXP3 on cell viability is 
highlighted in Figure 2.15. FOXP3 enhanced apoptosis in the absence of stimulation, but 
protected Jurkat T cells from apoptosis in the presence of PMA and ionomycin.
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DISCUSSION 
In this report we have shown that FOXP3 and Siva physically interact. We have 
mapped the binding activities to limited domains within each protein. Both FOXP3 and Siva 
repressed IL-2 gene expression. One likely mechanism by which Siva represses IL-2 is via 
inhibition of NFκB. FOXP3 repressed the activity of three IL-2 transactivators: NFκB, 
NFAT, and AP-1. FOXP3 did not affect Siva’s pro-apoptotis effect. An interesting effect was 
observed whereby FOXP3 enhanced apoptosis in the absence of stimulation, but protected 
from apoptosis induced by PMA and ionomycin. 
The physical interaction was demonstrated through a standard protein-protein 
interaction, co-immunoprecipitation assay. Two Siva isoforms have been identified and both 
Siva isoforms interact with FOXP3. The Siva-2 isoform lacks the second exon that encodes 
for the SAH and DDHR domains28,45. Both Siva isoforms share the C-terminal domain that 
contains FOXP3-binding capacity. The Siva C-terminus spans the putative B-box and ZnF 
domains. Siva retains FOXP3-binding ability when either the Siva B box domain or the ZnF 
domains are removed. 
Efforts were made to detect a biophysical interaction between endogenously 
expressed FOXP3 and Siva, but these were met with technical challenges. However, failure 
to detect an interaction does not mean that the interaction does not occur. Also, a functional 
interaction between FOXP3 and Siva could be independent of the physical, biochemical 
interaction between the two proteins. In order to test whether the biochemical interaction 
between FOXP3 and Siva affects their functional interaction, a minimal region of 
biochemical interaction for at least one protein needs to be identified. 
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The Siva C-terminus is enriched with cysteine residues that could be important to the 
tertiary protein structure and function (Figure 2.16). Paired cysteine residues are associated 
with intramolecular disulfide bond formation. The Siva B-box domain contains four paired 
cysteine residues. The ZnF domain contains two paired cysteine residues and one, single 
cysteine residue. Nestler et al55 used truncation mutants to show that Siva coordinates three 
zinc ions, two of which are associated with the C-terminus55. Although a few groups have 
found that the Siva C-terminus is necessary to interact with other binding partners48,56,57, no 
one has described whether specific C-terminal point mutations block Siva function. Site-
directed mutagenesis of the Siva C-terminal cysteine residues could be tested for physical 
interaction with FOXP3 and could be useful towards understanding a possible functional 
interaction between FOXP3 and Siva. 
FOXP3’s capacity to bind Siva is contained within a broad central region that 
includes the ZnF, the L.Zip and the AML1/RUNX1 binding domain (amino acids 106-332). 
Mutants missing either the first 105 N-terminal amino acids or the C-terminal Fkh domain 
sustained binding to Siva. Further experiments are needed to define a minimal region of 
FOXP3 involved in binding to Siva. The Foxp3 L.Zip domain is required for 
homodimerization, IL-2 repression, and Treg suppressive function11,21,43. Given that the L.Zip 
domain is within the region that binds Siva, one obvious next step we plan is to test whether 
known L.Zip IPEX mutations (Δ250, Δ251)11,21 interfere with FOXP3 binding to Siva. 
Even though both FOXP3 and Siva independently repress IL-2 transcriptional 
activity, modulation of the expression level of Siva affects the repressive effect of FOXP3 on 
IL-2. Siva overexpression reduced the relative inhibitory activity of FOXP3. Knocking down 
endogenous Siva enhanced FOXP3’s repressive effect on IL-2 transcriptional activity. These 
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data could mean that FOXP3 and Siva functionally interact to repress IL-2 by affecting 
similar gene regulatory mechanisms. Such a proposed functional interaction would not 
necessarily be dependent upon the observed biophysical interaction that we have 
characterized. 
Our analysis of three IL-2 transactivators supports the assertion that Siva and FOXP3 
affect shared and different IL-2 regulatory pathways. Consistent with previous reports, 
FOXP3 repressed NFκB13,16,22, NFAT21,36, and AP-115 transactivation reporters. Siva 
inhibited NFκB, but had no effect on either NFAT or AP-1 in cells stimulated with PMA and 
Ion. Our data indicating that Siva has no effect on AP-1 in activated Jurkat T cells conflicts 
with data showing that Siva enhanced AP-1 activity58. 
The effects of FOXP3 and Siva on IL-2 resembles FOXP3- and Siva-mediated 
repressive effects observed for the MHC3κB reporter. A small, but significant additive effect 
was observed when Siva and FOXP3 were added in combination. 
The small additive NFκB-repressive effect that we observed between FOXP3 and 
Siva could be related to cytoplasmic and nuclear NFκB signaling events. In resting cells, 
cytoplasmic IκBα sequesters the canonical NFκB subunits p65 and p50, preventing their 
nuclear translocation. In response to stimulus, activated IKK phosphorylates IκBα, triggering 
ubiquitin-mediated degradation of IκBα and release of the NFκB subunits59. One group 
showed that FOXP3 binds to the NFκB p65 subunit and inhibits NFκB transactivation 
potential by mechanisms independent of nuclear translocation and DNA binding13. 
Previously, we observed that FOXP3 affects NFκB transactivating potential independent of 
nuclear translocation, but dependent on the promoter sequence. FOXP3 enhanced HIV-1 
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gene expression by increasing the amount of NFκB p65 subunit bound to the LTR (long 
terminal repeat)10. Thus, the known effect of FOXP3 on NFκB activity occurs downstream of 
IκBα degradation, whereas Siva is known to inhibit NFκB activity by stabilizing IκBα and by 
blocking NFκB nuclear accumulation36.. 
Siva may have a transcriptional regulation function within the nucleus as others and 
we have observed the subcellular localization of Siva to be both nuclear and cytoplasmic46,48-
50,52. However, as of yet, neither DNA-binding by EMSA nor chromatin binding by 
chromatin IP assay has been reported for Siva. Even though Siva is present in the nucleus, 
most detailed reports regarding intracellular Siva function have investigated Siva function in 
relation to transmembrane cytoplasmic tails or mitochondrial-associated apoptosis regulators 
present in the cytoplasm, not the nucleus28,29,45,48,50,56,60-62. 
We have shown that freshly isolated CD4posCD25pos cells expressed Siva mRNA and 
that CD4posCD25neg cells upregulated Siva mRNA in response to TCR stimulation. FOXP3 
expression is also upregulated in human naïve CD4 T cells in response to activation63. Thus, 
Siva and FOXP3’s repressive effects on IL-2 could contribute to either conventional CD4pos 
T cell function or thymic derived nTreg function. 
In the future, we would like to extend our investigations of FOXP3- and Siva-
mediated IL-2 repression to primary T cells. We plan to evaluate Siva’s effect on IL-2 in 
CD4posCD25neg and CD4posCD25pos T cells. Also, another remaining question is whether Siva 
could mediate Treg suppressive function. 
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Figure 2.1: FOXP3 physically interacts with both Siva isoforms. 
A. Diagram showing the Siva protein domain organization [SAH, spherical amphipathic 
helix; DDHR, death domain homology region; B Box; and ZnF, zinc finger] and a 
cartoon representation of Siva-1 and Siva-2, which were fused to the C-terminus of 
EGFP and used in the Co-IP shown in B. 
B. FOXP3 interacts with Siva-1 and Siva-2 in 293T cells. Plasmids expressing 
EGFP/Siva fusion constructs in the presence or absence of Myc/FOXP3 were 
transfected into 293T cells. Cell lysates were prepared in modified RIPA buffer and 
protein concentrations were measured to standardize immunoprecipition (IP) 
reactions (500 µg) and inputs (15 µg). Myc/FOXP3 was IP’ed with a mouse anti-Myc 
9e10 hybridoma supernatant. To detect the proteins in IPs and inputs, western blot 
(WB) was performed with a mouse monoclonal antibody against GFP (Contech, JL-
8). Membranes were stripped and reprobed with a rabbit anti-Myc polyclonal 
antibody. For further details see Methods and Materials, 293T Transfections, Co-IPs, 
and Antibodies. Siva-1 binding to FOXP3 was observed in 5 or more experiments. 
Siva-2 binding to FOXP3 was observed in 3/3 Co-IPs. 
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Figure 2.2: Siva expression in human and mouse CD4 T cells. 
A. Expression of Siva mRNA in human CD4posCD25neg and CD4posCD25pos cells freshly 
isolated from peripheral blood mononuclear cells or stimulated with α-CD3 and α-
CD28 for 24-hours. Siva and β-actin expression was measured by semi-quantitative 
RT-PCR. Image quant was used to quantify band intensities and the ratio of Siva 
normalized to β-actin is shown. Experiment was performed one time. 
B. Normalized Siva spot intensity in mouse CD4pos T cells. Data was obtained from the 
BioGPS Mouse Gene Atlas. Spots were probed with RNA from CD4pos and Foxp3pos 
T cells. The spot intensity raw values from two Siva spots on the array were 
normalized to the respective spot value for CD4pos T cells. For more information see 
Methods and Materials, BioGPS Data Analysis. The normalized data was evaluated 
with a two-tailed Student’s t-test and * indicates the p-value < 0.05. 
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Figure 2.3: Siva-1 and FOXP3 co-localize in the nucleus of U2OS cells. 
U2OS cells were plated in chamber slides and co-transfected with plasmids expressing 
Myc/FOXP3, EGFP/Siva, and/or vector controls. Negative transfection controls and staining 
controls are not shown. Transfected cells were stained with Rhodamine-conjugated anti-Myc 
or Rhodamine-conjugated IgG isotype as a negative control. The same cell is shown in a-c; 
two adjacent cells are shown in d-f. Rhodamine α-Myc detection of Myc/FOXP3 (a,d); 
EGFP/Siva (b,e); Overlay (c,f). Printed with permission from Dr. Stephanie Mackey 
Cushman. 
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Figure 2.4: Siva-binding activity is contained within a central portion of the FOXP3 
protein (amino acids 106-332) 
A. Diagram depicting FOXP3 protein domain organization and truncation mutants that 
were fused to the C-terminus of Myc and used in the Co-IP shown in B. (Zn F, zinc 
finger; L.Zip, leucine zipper; b.dom, binding domain; Fkh, forkhead) 
B. EGFP/Siva-1 co-immunoprecipitates (Co-IPs) with full-length FOXP3 and FOXP3 
truncation mutants containing the ZnF, L.Zip, and AML-1/RUNX1-binding domains. 
The FOXP3 Fkh domain and N-terminus are dispensable for binding to Siva. Co-IPs 
were performed as described in Figure 2.1. (WB, western blot). Binding between the 
Fkh FOXP3 mutant and Siva was tested three times. Other FOXP3 mutants shown 
here were tested once. 
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Figure 2.5: The Siva C-terminus is sufficient to bind FOXP3. 
For experiments shown in B and C, see the Co-IP procedure described in Figure 2.1.  
A. Diagram showing the Siva protein organization and Siva truncation mutants, which 
were fused to the EGFP C-terminus and tested in Co-IPs shown in B and C. 
B. Siva mutants containing portions of the C-terminus Co-IP with Myc/FOXP3. These 
Siva truncation mutants were tested 3 times for FOXP3-binding activity. 
C. Co-IP to test the FOXP3-binding capacity of the Siva B-box and ΔB-box mutants. 
These mutants were tested twice for FOXP3-binding activity. 
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Figure 2.6: Siva represses endogenous IL-2. 
Siva was subcloned into the pHSPG (PG) retroviral (RV) vector. pHSPG-Siva RV was 
prepared and used to transduce Jurkat T cells that were subsequently used for experiment 
shown in C. For C and D, transduced, Jurkat T cells were activated with PMA and Ion for 18 
hours. Endogenous IL-2 expression was measure by ELISA. 
A. Characterization of pHSPG-Siva by western blot (WB) of transfected 293T cell 
lysates with rabbit anti-Siva (FL-175, Santa Cruz). 
B. Evaluation of pHSPG transduction efficiency by flow cytometry for GFP expression 
in Jurkat T cells. Plots shown were gated on FSChi7AADneg cells. 
C. Endogenous IL-2 expression for the pHSPG-Siva transduced Jurkat T cells shown in 
B. * indicates p<0.05 for two-tailed Student’s t-test for Siva-transduced cells 
compared to (PG) controls. Experiment was performed once. 
D. Endogenous IL-2 expression for Jurkat T cells transduced with pLKO lentivirus (LV) 
containing U6-driven shRNA for EGFP or Siva. Cells were selected in puromycin 
(µg/ml) for one week. Standard RT-PCR evaluated Siva knockdown efficiency and 
DNA bands are shown. * indicates p<0.05 for two-tailed Student’s t-test  between 
shEGFP and shSiva. Experiment was performed >5 times. 
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Figure 2.7: Siva represses IL-2 promoter activity. 
To evaluate IL-2 promoter activity, Jurkat T cells were transfected by electroporation with an 
IL-2 reporter plasmid (IL-2 proximal promoter upstream of luciferase) plus other constructs 
to overexpress or knockdown (KD) Siva expression. After recovering from the 
electroporation for ~18 hours, transfected Jurkat T cells were activated with PMA and Ion for 
6 hours. IL-2 driven luciferase activity in the cell lysates was measured on a luminometer. 
For more details, see Methods and Materials, Jurkat Transfections and Luciferase Reporter 
Assays. 
A. Siva overexpression with pHSPG-Siva repressed IL-2-promoter activity. * indicates 
p<0.05 for two-tailed Student’s t-test between vector and Siva transfected cells. 
B. Siva KD by shRNA had an enhancing, dose-responsive effect on IL-2 promoter 
activity. Brackets and *s indicate statistical difference between designated pairs based 
on p<0.05 by a two-tailed Student’s t-test. 
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Figure 2.8: Endogenous IL-2 in response to FOXP3 and Siva overexpression. 
Jurkat T cells were transduced twice: first with pHSPG or pHSPG-Siva RV, then with 
pHSPG or pHSPG-FOXP3. (See Methods and Materials, Retrovirus Production and 
Transduction). All data shown was derived from the same experiment. 
A. Flow cytometry for GFP expression in Jurkat cells transduced with pHSPG-derived 
RV expressing FOXP3 and/or Siva. Plots shown were gated on FSChi7AADneg cells. 
B. Endogenous IL-2 in response to FOXP3 and Siva overexpresion. Dual transduced, 
Jurkat T cells were activated with PMA and Ion for 18 hours. Endogenous IL-2 
expression was measure by ELISA. Brackets and *s indicate statistical difference 
between designated pairs based on p<0.05 by a two-tailed Student’s t-test. 
C. FOXP3-mediated IL-2 repression was determined by calculating fold repression in 
the presence and absence of Siva. Ex. (PG:PG)/(PG:FOXP3) vs. 
(Siva:PG)/(Siva:FOXP3), using the IL-2 concentrations shown in B.
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Figure 2.9: Endogenous IL-2 in response to FOXP3 overexpression and Siva 
Knockdown (KD). 
First Jurkat T cells were transduced with pLKO-shEGFP or pLKO-shSIVA LV and then 
selected in puromycin for ~1 week. Next, the same cells were transduced with pHSPG or 
pHSPG-FOXP3 RV. (See Methods and Materials, Retrovirus Production and Transduction). 
All data shown was derived from the same experiment, which was performed 3 times. 
Brackets and *s indicate statistical difference between designated pairs based on p<0.05 by a 
two-tailed Student’s t-test. 
A. Siva KD efficiency was determined by quantitative realtime PCR for Siva and 18S. 
cDNA was prepared from mRNA isolated from each cell line. The cDNA template 
was diluted 1:1000 for 18S reactions. Relative quantities were determined by 
correlating CT values to a standard curve. Data shown is the relative quantity of Siva 
normalized to relative quantity of 18S. 
B. Endogenous IL-2 in response to FOXP3 and Siva KD. Dual transduced Jurkat T cells 
were activated with PMA and Ion for 18 hours. Endogenous IL-2 expression was 
measure by ELISA. 
C. The IL-2-repressive effect of FOXP3 was determined by calculating IL-2 fold 
repression in the presence or absence of Siva KD. Example calculation: 
(shEGFP:PG)/(shEGFP:FOXP3) vs. (shSiva:PG)/(shSiva:FOXP3) using IL-2 
concentrations from B. 
D. The IL-2-enhancing effect of Siva KD was determined by calculating IL-2 fold 
enhancement in the presence and absence of FOXP3 overexpression. Example 
calculation: (shSiva:PG)/(shEGFP:PG) vs. (shSiva:FOXP3)/(shEGFP:FOXP3). 
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Figure 2.10: IL-2 promoter activity in response to FOXP3 and Siva overexpression. 
IL-2 promoter activity was evaluated using a luciferase reporter driven by the IL-2 proximal 
promoter, similar to the methods described in Figure 2.7. In addition to the IL-2 luciferase 
reporter plasmid, Jurkat T cells were transfected with Vector (pHSPG) or pHSPG-Siva and 
titrated amounts of pHSPG-FOXP3. Experiment was performed once. 
A. IL-2 promoter activity in response to FOXP3 and Siva overexpression. Brackets and 
*s indicate statistical difference between designated pairs based on p<0.05 by a two-
tailed Student’s t-test. 
B. FOXP3-mediated IL-2 repression is inhibited by the presence of Siva when the 
FOXP3 dose is not maximized. “Vector” (dark diamonds) data points were calculated 
by setting the IL-2 RLU for PG/vector (first dark bar from A) as 100% IL-2 luciferase 
activity. “Siva” (light squares) data points were calculated by setting the IL-2 RLU 
for PG/Siva as 100% IL-2 luciferase activity. * indicates p<0.05 for Student’s t-test 
comparing FOXP3’s repressive effect in the presence of vector or Siva (diamonds vs. 
squares). 
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Figure 2.11: IL-2 promoter activity in response to FOXP3 overexpression and Siva 
knockdown (KD). 
IL-2 promoter activity was evaluated using methods similar to those described for Figures 2.7 
and 2.10. Jurkat T cells were transfected with the IL-2 luciferase reporter plasmid, a vector 
containing a negative control hairpin sequence (shNS) or shSIVA and pHSPG or pHSPG-
FOXP3. 
A. IL-2-driven luciferase activity in response to FOXP3 overexpression and Siva KD. 
Brackets and *s indicate statistical difference between designated pairs based on 
p<0.05 by a two-tailed Student’s t-test. 
B. FOXP3’s repressive effect on IL-2 promoter activity was determined by calculating 
fold repression in the presence or absence of Siva KD. Ex. (shNS:PG)/(shNS:FOXP3) 
vs. (shSIVA:PG)/(shSIVA:FOXP3). * indicates statistical difference between bars 
shown based on p<0.05 by a two-tailed Student’s t-test. 
C. Siva KD’s enhancing effect on IL-2 promoter activity was determined by calculating 
fold repression in the presence or absence of FOXP3. Ex. (shSIVA:PG)/(shNS:PG) 
vs. (shSIVA:FOXP3)/(shNS:FOXP3). * indicates statistical difference between bars 
shown based on p<0.05 by a two-tailed Student’s t-test. 
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Figure 2.12: Transcriptional activity of three IL-2 regulatory elements in response to 
FOXP3 and Siva. 
Jurkat cells were transfected by electroporation with a luciferase reporter plasmid and 
plasmid expressing FOXP3, Siva or the parental vector control, using methods previously 
described (Figures 2.7, 2.10 and 2.11). Brackets and *s indicate statistical difference between 
indicated pairs based on p<0.05 by a two-tailed Student’s t-test. Data shown represents 
experiments that have been performed twice. 
A. Effect of FOXP3 and Siva on NFκB activity in response to PMA/Ion. The reporter 
was comprised of 3 tandem repeats of the MHC-κB response element (MHC-3κB). 
B. Effect of FOXP3 and Siva on NFAT activity in response to P/I. The reporter was 
comprised of 3 tandem repeats of the IL-2 promoter NFAT response element. 
C. Effect of FOXP3 and Siva on AP-1 activity in response to P/I. The reporter was 
comprised of 3 tandem repeats of the TPA response element. 
D. Effect of FOXP3 and Siva on AP-1 activity in the absence of stimulation. 
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Figure 2.13: Siva’s pro-apoptotic effect is not significantly altered by FOXP3 in 
unstimulated Jurkat T cells. 
The viability of Jurkat T cells transduced with pHSPG, pHSPG-Siva, and/or pHSPG-FOXP3 
(transduction efficiency shown in Figure 2.8A) was determined by staining with 7AAD 
(marker of late apoptosis). Brackets and *s indicate statistical difference between pairs based 
on p<0.05 by a two-tailed Student’s t-test. Data shown represents experiments that have been 
performed twice.
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Figure 2.14: Effects of Siva and FOXP3 on apoptosis in PMA/Ion-treated Jurkat T cells. 
Transduced Jurkat T cells shown in Figures 2.8 and S2.13 were activated with PMA/Ion for 
18 hours and viability was assessed by 7AAD staining. Brackets and *s indicate statistical 
difference between designated pairs based on p<0.05 by a two-tailed Student’s t-test. Data 
shown represents experiments that have been performed twice. 
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Figure 2.15: Differential effect of FOXP3 on Jurkat T cell viability is dependent upon 
stimulation conditions. 
Jurkat T cells were transduced with pHSPG (PG) or pHSPG-FOXP3 (efficiency >95% for 
both populations). Transduced cells were plated in 96-well plates at a density of 2x105 
cells/well. Cells were left unstimulated or activated with PMA (25 ng/ml) and Ion (1 µM) for 
~18 hours. Cell viability was evaluated by staining with 7AAD, a marker of late apoptosis. * 
indicates p<0.05 for two-tailed Student’s t-test between PG- and FOXP3-transduced cells. 
Experiment was performed three times. 
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Figure 2.16: Siva-1 protein sequence highlighting the presence of cysteine residues in 
the C-terminus. 
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CHAPTER THREE 
FOXP3 REGULATION OF HER2/NEU IN THYMIC EPITHELIAL CELLS (TECS) AND HER2/NEU 
FUNCTION IN TECS
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ABSTRACT 
In this chapter, I will present data pertaining to Foxp3 regulation of Her2/neu in 
TECs and the effect of Her2/neu signaling on thymopoiesis. Previously, it was reported that 
Her2/neu is upregulated in TECs from scurfy mice, a Foxp3-deficient strain. Based on the 
finding that Herceptin, a Her2/neu-specific monoclonal antibody, partially rescued defective 
thymopoiesis in scurfy mice1, we hypothesized that Her2/neu signaling could be involved in 
TEC function. To investigate the effect of Her2/neu on thymopoiesis, we treated fetal thymic 
organ cultures (FTOC) with a small molecule inhibitor of Her2/neu and EGFR, GW572016 
(GW57). GW57 treatment moderately enhanced thymopoiesis in the FTOC. 
Also, we investigated the relationship between Foxp3 and Her2/neu expression in 
TEC lines representative of cortical, medullar, and sub-capsular thymic regions. We observed 
an inverse relationship between Foxp3 and Her2/neu across three TEC lines. Foxp3 
overexpression repressed Her2/neu in two out of three TEC lines tested (cortical 1308 and 
sub-capsular 427), but not in the TEC line expressing the highest amount of Foxp3 and 
lowest Her2/neu (medullary 1307). 
In summary, data from the TEC lines supports the assertion that Foxp3 represses 
Her2/neu. Further, inhibition of Her2/neu and EGFR by GW57 positively affected 
thymopoiesis in some FTOC models. These experiments suggest that improved 
understanding of how Her2/neu and EGFR contribute to thymopoiesis could eventually lead 
to improved thymus-targeted therapies that would be beneficial for patients with 
immunodeficiencies due to HIV-1 infection or chemotherapy.
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INTRODUCTION 
A functional thymus is essential for limiting infections and preventing autoimmune 
disease. Thymus function depends on the differentiation and integrity of thymic epithelial 
cells (TECs). TECs form a three dimensional reticular structure that houses thymocytes and 
provides developmental cues that guide T cell lineage commitment, differentiation, 
proliferation and selection2,3. In spite of the important contributions of TECs to thymopoiesis, 
relatively little is known about TEC biology compared to the T cells that TECs support4. 
In humans, FOXP3 mutations cause a severe autoimmune disease called immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) 5-7. Similarly, 
the scurfy mouse strain carries a Foxp3 frameshift truncation mutation and affected males 
succumb to lethal, multi-organ T cell proliferative disease6,8. 
Most investigators attribute the severe autoimmune syndrome in IPEX patients and 
Scurfy mutants to T-cell intrinsic Foxp3 deficiency. Foxp3 is required for the development, 
function, and maintenance of natural regulatory T cells (nTregs), a critical CD4pos population 
that suppresses autoreactive T cells and prevents destructive inflammation. The absence of 
Tregs associated with Foxp3 deficiency has been proposed as the central causal factor for 
autoimmunity in mice and humans9-12. 
In addition to the T-cell intrinsic function of Foxp3, support for Foxp3 function in 
TECs first came from transgenic radiation chimeras. Scurfy bone marrow failed to transfer 
autoimmunity into irradiated SCID (severe combined immunodeficiency) mice, indicating 
that radioresistant non-bone marrow-derived cells (which may have included TECs) required 
the Scurfy mutation to elicit autoimmunity. However, the later discovery that radiation 
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induced T cell production in SCID mice compromised interpretation of the scurfy/SCID 
chimeras. The experiments were repeated in RAG-/- (recombination activating gene) mice. 
Again, scurfy bone marrow failed to transfer autoimmunity (Reviewed in 13). 
In another set of experiments, the scurfy allele (Foxp3Sf) was crossed on to the RAG-/- 
background and bone marrow transplant experiments demonstrated impaired thymopoiesis in 
RAG-/-Foxp3Sf recipients. T-cell depleted bone marrow was transferred from GFP (green 
fluorescent protein) transgenic mice into sublethally irradiated recipients (RAG-/-Foxp3wt 
compared to RAG-/-Foxp3Sf). Thymocyte distribution and proliferation was measured to 
evaluate stromal cell function. The distribution of mature single positive (SP, cells single 
positive for either the CD4 or CD8 coreceptor) thymocytes was normal. In contrast, the 
earliest stage of thymopoiesis was defective. The immature double negative (DN, marked by 
the absence of CD4 and CD8 coreceptors) compartment in RAG-/-Foxp3Sf mice contained 
fewer proliferative cells based on BrdU (5-bromo-2-deoxyuridine) incorporation compared to 
RAG-/-Foxp3wt. Foxp3 mRNA and protein were detected in TECs by realtime PCR and 
immunofluorescence, respecitively1. These data led to the proposal that T-cell extrinsic 
properties of Foxp3 also contribute to autoimmunity in mice and humans1,13,14. 
Following a serendipitous observation that female Foxp3Sf heterozygotes developed 
spontaneous mammary carcinomas, Zuo et al15 discovered that Foxp3 exerted tumor 
suppressor properties by repressing Her2/neu, an oncogene associated with breast cancer15. 
The Her2/neu-repressive effect of Foxp3 in breast epithelium prompted analysis of Her2/neu 
expression in thymic epithelium. 
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Her2/neu overexpression by TECs was observed in the scurfy mice and was proposed 
as a mechanism by which Foxp3 contributed to TEC function1. Her2/neu (name derived from 
human epidermal growth factor receptor-2/neu oncogene) is an orphan receptor from the 
receptor tyrosine kinase, epidermal growth factor receptor (EGFR) family. As a family, 
EGFRs regulate diverse cell fate programs including differentiation and proliferation. 
Her2/neu overexpression is associated with malignancy. Herceptin is a monoclonal antibody 
that inhibits Her2/neu signaling and was developed to treat Her2/neupos cancers16. Herceptin 
treatment partially rescues defective DN thymocyte proliferation in scurfy mice. 
Thus, at the start of my project, data existed in support of the following premises: 
1. TECs express Foxp3 and Foxp3 contributes to TEC function. 
2. Foxp3 represses Her2/neu protein expression. 
3. Her2/neu antagonism improved defective thymopoiesis in Foxp3Sf mice. 
During the course of research, Foxp3 expression and function in TECs was 
challenged by evidence from three different transgenic Foxp3 promoter-driven GFP reporter 
mice10,11 and by the discovery of radiation-resistant Foxp3pos cells12. Regardless of the 
controversy over Foxp3 function in TECs, the negative regulatory effect of Foxp3 on 
Her2/neu has not been contested and the effects of Her2/neu on thymopoiesis have yet to be 
fully elucidated17,18. 
To study the effect of Foxp3 overexpression on Her2/neu expression, we used three 
TEC lines associated with different cortical, medullary, and subcapsular thymic regions19. 
We observed an inverse relationship between Foxp3 and Her2/neu across the three TEC 
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lines. Ectopic expression of Foxp3 by retroviral (RV) transduction yielded Her2/neu 
repression in two TEC lines, but not in the TEC line expressing the highest level of Foxp3. 
Next, because epigenetic modifications are associated with gene regulation, we tested 
the effect of two chromatin remodeling inhibitors on Her2/neu expression: Trichostatin A 
(TSA) and 5-azacytidine (AZA). TSA suppresses histone deacetylase (HDAC) activity and 
AZA inhibits DNA methylation. Epigenetic transcriptional regulation is poorly understood. 
Histone acetylation is associated with transcriptionally active chromatin and reduced histone 
acetylation is associated with inactive chromatin. Conversely, methylated DNA is associated 
with transcriptional repression20. 
In order to investigate Her2/neu function in thymopoiesis, we used two types of fetal 
thymic organ culture (FTOC) systems. In the simplest FTOC model, unmanipulated fetal 
thymic lobes were cultured on a membrane in vitro. The simple FTOC model does not 
segregate TECs from thymocytes. The hanging drop FTOC involves more manipulations, but 
permits modification of TECs separate from thymocytes21. Therefore, the hanging drop 
FTOC is an ideal system for studying TEC-intrinsic factors. 
Research in the field of oncogenic inhibitor drugs has led to the creation of 
compounds that specifically target known transformation signaling pathways. The small 
molecule, GW572016 (referred to as GW57) was developed by Glaxo Smith Kline, formerly 
Glaxo Wellcome, to inhibit EGFR and Her2/neu mediated proliferation22-24. 
We tested the effect of dual Her2/neu and EGFR inhibition by applying GW57 to 
thymic lobes in the standard FTOC and hanging drop FTOC system. Inhibition of 
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EGFP/Her2/neu moderately improved thymopoiesis in the FTOC system under some 
conditions. 
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METHODS AND MATERIALS 
Cell lines and culture conditions 
The TEC cell lines 427.1, 1307.6.1.11, and 1308.1.6 were originally derived from 
SV40 T-antigen transgenic (SV40T-Tg) mice19. 
Line 427.1 was derived by directly culturing dissociated hyperplastic thymus tissue 
from SV40T-Tg mice. Routine trypsin treatment removed contaminating fibroblasts. The 
dominant epithelial cell line that remained after repeated rounds of trypsanization was 
derived by single-cell limiting dilution. To derive parental TEC lines 1307 and 1308, 
hyperplastic thymic tissue was taken from SV40T-Tg mice, dissociated, and serially passed 
in nude mice. The thymus cells were either injected into the peritoneal cavity or surgically 
placed under the kidney capsule. Tumors formed, which were serially transferred into nude 
mice two more times. Abdominal tumors were taken from the third recipient, dissociated and 
cultured. Limiting dilution was performed to isolate parental clones. Based on morphology 
and ultrastructural features, the clones were proposed to represent distinct thymic epithelial 
populations19. 
427.1 cells were described as thymic subcapsular cortex or thymic nurse cells; 1308.1 
were thought to be deep cortex or cortical reticular cells; and 1307.6.1.11 shared 
characteristics with cells of medullar origin. TEC lines 427.1, 1307.6.1.11, and 1308.1.6 will 
be referred to as 427, 1307, and 1308, respectively. 
Adherent TEC lines, and 293T cells were cultured at 37° in 5%CO2 in DMEM-10% 
FBS supplemented with 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml 
streptomycin. 
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Trichostatin A and 5’-Azacytidine were purchased from Sigma. GW572016 (GW57) 
was a gift from Shelton Earp24. 
Gene expression measurements by PCR 
The Qiagen RNeasy isolation kit was used to isolate mRNA from all cell lines. 
Reverse transcription (RT) reactions were performed with random primers and M-MLV 
reverse transcriptase in the presence of RNase inhibitor. Quantitative Taq-Man PCR was 
performed using primers from Applied Biosystesms. Semi-quantitative RT PCR was 
performed by serially diluting the cDNA template ten fold. The following primer sequences 
were used in semi-quantitative RT PCRs: 
Her2/neu For, 5’-GCTGCTGGACATTGATGAGA-3’ 
Her2/neu Rev 5’-GGGATCCCATCGTAAGGTTT-3’ 
HPRT For, 5’-CAGGCCAGACTTTG-3’ 
HPRT Rev, 5’-TTGCGCTCATCTTAGGCTTT-3’ 
Retrovirus production and transduction 
The pHSPG and pHSPG-mFoxp3 retrovirus (RV) used to transduce TEC lines was 
prepared in 293T cells by the calcium phosphate transfection method, which has been 
described previously21,25. Briefly, DNA complexes were prepared by mixing plasmids for the 
RV vector, VSV-G, and gag/pol with HBSS and calcium chloride. Adherent 293T cells were 
treated with chloroquine thirty minutes prior to the addition of DNA. Supernatants were 
collected at 48 and 72 hours. 
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Western blot, antibodies, and 293T cell transfections 
For protein analysis by western blot, cell pellets were washed in PBS and stored at -
20°. In this report, all cell pellets were lysed in NP-40 lysis buffer (50 mM Tris-HCl, 150 
mM NaCl, 0.5% NP-40, and 50 mM NaF). Protein concentrations were determined using the 
Pierce BCA kit and 50 µg lysate was mixed with 2X SDS loading dye. Samples were boiled 
and separated by electrophoresis on a 10% Bis-Tris NuPage gel. Gel contents were 
transferred to a PVDF membrane (Amersham Hybond-P). 
Membrane blocking (~30 minutes, room temperature) and all subsequent antibody 
incubation steps were performed in PBS/0.2%Tween-20/5% milk. Primary antibody 
incubations were performed overnight at 4°, followed by four ~7 minute washes in 
PBS/0.2%Tween-20. Her2/neu expression was detected with Rabbit αHer2/neu RB-103-P 
from NeoMarkers (1:1000). The polyclonal Foxp3 serum (diluted 1:2000) used in this report 
was generated by immunizing rabbits with a Foxp3 N-terminal peptide 
(CLLGTRGSGGPFQGRDLRSGAH)26. Mouse monoclonal antibodies against β-actin 
(Sigma, AC-74, 1:10,000) and Myc (9E10 hybridoma supernatant kindly provided by Dr. 
Yue Xiong, 1:500) were also used. Goat anti-mouse-HRP or donkey anti-rabbit-HRP were 
used to detect mouse- and rabbit-derived primary antibodies, respectively (diluted 1:10,000). 
293T cell transfections were performed using Qiagen Effectene, according to the 
manufacturer’s intructions. 293T cells were harvested at 48-hours post-transfection.  
Generation of mouse Foxp3 short hairpin RNA targeting construct 
The mFoxp3 gene sequence (NM_054039) was entered into the Dharmacon 
siDESIGN® Center online tool to obtain short sequences predicted to have interference 
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activity. A target sequence was selected because it spanned a region of incomplete homology 
between the mFoxp3 and hFOXP3 DNA sequence (3 out of 15 base pair differences). Oligos 
encoding the sense, the stem-loop, and the anti-sense sequences were designed to be 
subcloned into the pLL5.0 lentiviral vector27, which was kindly provided by Dr. Jim Bear 
(5’-TGGACCGTAGATGAATTTGGTTCAAGAGATCAAATTCATCT 
ACGGTCCTTTTTTC-3’, underlined amino acids indicate location of the hairpin loop). 
PAGE purified oligos with 5’ phosphates were purchased from Operon. 
Fetal thymic organ culture (FTOC) and analysis 
Variations on the fetal thymic organ culture (FTOC) system have been reported 
previously by numerous groups, including ourselves21,28. Time of pregnancy was recorded in 
order to collect fetal thymic lobes on embryonic day 14 (E14). During the dissection 
procedure, lobes were collected in PBS on ice. Thymic lobes were cultured on Millipore 
membranes in mFTOC media (RPMI-10% FBS supplemented with 2 mM L-glutamine, 100 
U/ml penicillin, 100 mg/ml streptomycin, 50M β-mercaptoethanol, 1% nonessential amino 
acid, 10 mM Hepes, and 1 mM sodium pyruvate solution). The culture media was changed 
every two days. GW57 or DMSO vehicle was added to media where indicated. 
Fetal liver (FL) cells were also collected from E14 pups. Mouse FL cells were 
cultured in mFTOC media supplemented with hIL-11 (10 ng/ml), mIL-6 (50 ng/ml), and 
mSCF (stem cell factor, 50 ng/ml). All cytokines were purchased from Peprotech. 
For the hanging drop experiments (outlined in Figure 3.9), lobes were depleted of 
dividing cells by 2- deoxyguanosine (2dG, 1.35 mM) treatement for 5 days. Depleted lobes 
were washed in PBS and half of the lobes were exposed to γ-irradiation (500R in 
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experiments reported here; Lobes also survived 750R). To seed lobes, E14 FL cells were 
seeded to a density of 105 cells/40 µl mFTOC media/well in Terasaki plates. A single lobe 
was carefully added to each well. Plates were inverted to allow migration of progenitor cells 
into the lobe. After 48-hours, lobes were washed in PBS/2% FBS and placed back on 
membranes. As described above, media was changed every two days and GW57 or vehicle 
control was applied where indicated. 
At the end of three weeks, lobes were transferred to 500 µl PBS/2% FBS in 
microcentrifuge tubes. A plastic pestel (Bellco Glass, Inc, Cat# 1980-45015) was used to 
manually release thymocytes from the thymic capsule. Cells were counted in Gauva 
ViaCount reagent on a Gauva EasyCyte. Cells were stained with CD4-FITC and CD8-
PERCP and analyzed on a Becton-Dickson FACScan.
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RESULTS 
Correlation between endogenous Foxp3 and Her2/neu in TEC Lines 
Before performing any genetic manipulations with the TEC lines, we evaluated 
Foxp3 and Her2/neu gene expression by quantitative realtime PCR. Judged against total 
adult thymocytes, Foxp3 expression in all three TEC lines was very low (Figure 3.1A). 
Comparison between the three TEC lines indicated that Foxp3 was highest in the medullary-
like 1307 line and lowest in the subcapsular-like 427 line. Next, we measured Her2/neu 
expression. We found Her2/neu was highest in 427 TECs and lowest in 1308 TECs. Thus, an 
inverse relationship exists between Foxp3 and Her2/neu across the three TEC lines (Figure 
3.1B). Although this relationship is consistent with a repressive effect of Foxp3 on Her2/neu, 
Foxp3-independent factors could account for the observation. 
Effect of ectopic Foxp3 expression on Her2/neu in TECs 
Next, we tested the hypothesis that Foxp3 affects Her2/neu expression in TEC lines. 
Each line was transduced with pHSPG control or pHSPG-mFoxp3 retrovirus (RV). 
Transduced cells were collected three days after transduction and saved for mRNA or protein 
analysis. 
Her2/neu protein was repressed by Foxp3 expression in the cortical TEC line, 1308 
(Figure 3.2). Transfected 293T cells were used as a western blot staining control. It is worth 
noting that Her2/neu expression did not change in 293T cells transfected with Foxp3. Foxp3 
overexpression repressed Her2/neu mRNA in thymic subcapsular-like 427 cells, but not in 
medullary-like 1307 cells, which already have low Her2/neu expression (Figure 3.3). Out of 
the three TEC lines, 1307 cells expressed the highest level of Foxp3. The absence of a 
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Foxp3-mediated repressive effect on Her2/neu in 1307 cells might be due to sufficient levels 
of endogenous Foxp3 already present, which have saturated the repressive effect. In order to 
test the hypothesis that Foxp3 in 1307 cells affected Her2/neu expression, we planned to 
knockdown Foxp3 expression in 1307 cells with short hairpin RNA (shRNA). 
Mouse Foxp3 knockdown by shRNA 
The sh-mFoxp3 sequence was subcloned into the pLL5.0 lentiviral (LV) vector, under 
control of the U6 promoter (Figure 3.4A)27. To test the specificity and efficiency of pLL5.0-
sh-mFoxp3, we co-transfected 293T cells with pLL5.0-sh-mFoxp3 or pLL5.0-NS (not 
specific) and either pcDNA-Myc/hFOXP3 or pcDNA-Myc/mFoxp3. Western blot analysis 
clearly shows that pLL5.0-sh-mFoxp3 reduces mouse Foxp3, but not human FOXP3 protein 
(Figure 3.4B) 
Chromatin modifying inhibitors 
While the histone code hypothesis predicts that inhibition of histone deacetylation 
and DNA methylation open up chromatin and relieve transcriptional repression for most 
genes, individual genes are differentially sensitive to epigenetic remodeling mechanisms. 
Therefore, we tested the effects of chromatin remodeling inhibitors TSA and AZA on 
Her2/neu and Foxp3 expression in 427 cells. Both TSA and AZA repressed Her2/neu in 427 
cells (Figure 3.5A&B). In contrast, Foxp3 expression was enhanced by both TSA and AZA 
(Figure 3.5C&D).
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Effect of Her2/neu/EGFR inhibition on thymopoiesis in FTOC 
Her2/neu and EGFR share similar tyrosine kinase signaling domains in their 
cytoplasmic tails. The small molecule GW57 efficiently blocks downstream MAPK (mitogen 
activated protein kinase) signaling and cell proliferation through inhibiting the kinase activity 
of both Her2/neu and EGFR22-24. Based on observations that Her2/neu was elevated in the 
scurfy mouse and that Herceptin treatment partially rescued deficient thymopoiesis1, we 
hypothesized that inhibition of Her2/neu with GW57 would enhance thymopoiesis in the 
FTOC. We took E14 thymic lobes and cultured the lobes on membranes in the presence of 
DMSO drug vehicle or titrated doses of GW57. At the end of the experiment, we harvested 
the lobes and analyzed thymocyte output. Dual inhibition of Her2/neu/EGFR signaling 
moderately enhanced thymocyte number with statistical significance at 5µM and 25µM 
GW57, but not 1µM (Figure 3.6). The increase in thymocyte output corresponded to 
decreased number of immature double negative (DN, CD4NegCD8Neg) cells and increased 
number of double positive cells (DP, CD4PosCD8Pos)(Figure 3.7B&C). At 25µM GW57, CD4 
single positive (SP) cell number per lobe was increased compared to the DMSO control 
(Figure 3.7D). GW57 did not affect CD8 SP cell number per lobe (Figure 3.7E). 
Effect of Her2/neu/EGFR inhibition on thymopoiesis in irradiated FTOCs 
One reason the GW57 treatment in FTOC did not show a greater effect on 
thymopoiesis could be due to relatively low expression level of Her2/neu in fetal thymic 
epithelium. Her2/neu sensitizes breast epithelial cells to radiation29 and we observed 
increased Her2/neu in the thymus in response to whole body irradiation (Figure 3.8). Given 
Her2/neu’s radiosensitizing role and that the effect of GW57 on thymopoiesis was small 
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(~25% increase in thymocyte number), we hypothesized that GW57 might enhance 
thymopoiesis to a greater degree following irradiation. To test the effect of irradiation and 
GW57 on thymopoiesis, we used the hanging drop FTOC system, which is outlined in Figure 
3.9. 
Irradiation of the thymic stroma caused a two-fold decrease in thymocyte output, but 
the effect was not statistically significant (Figure 3.10). In non-irradiated lobes (Figure 
3.11A), 5µM GW57 treatment caused a small, but statistically significant decrease in 
thymocyte number. 10µM GW57 had no effect on thymocyte number in non-irradiated lobes. 
In contrast, 5µM GW57 enhanced thymocyte output in irradiated lobes (Figure 3.11B). 10µM 
GW57 also enhanced thymocyte output in irradiated lobes, but the effect was not statistically 
significant. No preferential effect on thymocyte distribution was observed (Figure 3.12). 
Thus, dual inhibition of Her2/neu and EGFR moderately enhanced thymopoiesis in irradiated 
lobes, but not in non-irradiated lobes. 
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DISCUSSION 
This project generated support for the hypothesis that Foxp3 represses Her2/neu gene 
expression in TECs. Further, we demonstrated that HDAC and DNA methyltransferase 
inhibition repressed Her2/neu, which is consistent with the observed effects of HDAC 
inhibition on Her2/neu in breast cancer epithelial cells30,31. Finally, inhibition of Her2/neu 
(but also EGFR) signaling by GW57 treatment moderately enhanced thymopoiesis in some 
fetal thymic organ culture (FTOC) models.  
In the hanging drop FTOC model, 5 µM GW57 enhanced thymic output in irradiated 
lobes, but repressed thymic output in the absence of radiation (Figure 3.11). It is difficult to 
draw meaningful conclusions from this data because EGFR and Her2/neu are both inhibited 
by GW57 and the expression kinetics of each in response to radiation in the FTOC model 
was not measured. Therefore, more information regarding the kinetics and function of EGFR 
and Her2/neu in TECs is needed. Experiments evaluating the effects of individual EGFR and 
Her2/neu inhibtors in the FTOC model would greatly improve upon the current 
understanding of how each of these signaling molecules contributes to thymopoiesis29. Such 
experiments could lead to improved thymopoietic enhancement therapies, which might help 
treat immunodeficiency in HIV-1 infected individuals and patients receiving chemotherapy32.  
Her2/neu and thymus biology 
The effect of dysregulated Her2/neu expression on TEC biology is still an open 
question. Her2/neu overexpression in TECs is associated with poor thymic function. Kertain-
5 is found in skin epithelium and in TECs, where it is associated with the medulla and the 
cotico-medullary junction33. Transgenic mice carrying bovine keratin-5-driven Her2/neu 
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overexpress Her2/neu in medullary TECs. Keratin-5-Her2/neu transgenic mice had thymic 
abnormalities including increased thymocyte apoptosis and loss of thymic cortico-medullary 
organization18. Another group used Cre/lox technology to delete Stat3 in Keratin-5 
expressing TECs. TEC specific Stat3 deletion caused thymic hypoplasia, impaired thymocyte 
regeneration after irradiation and increased Her2/neu expression17. Taken together, these 
results show an association between excessive Her2/neu expression and impaired TEC 
function. 
Beyond the negative effect of Her2/neu overexpression in TECs, little is known about 
Her2/neu function in TEC biology. In breast cancer cells, Her2/neu promotes cell 
proliferation16,29. One reason Her2/neu negatively affects thymopoiesis could be due to 
enhanced proliferation of TECs that are immature, or otherwise impaired in their ability to 
support thymopoiesis by some, as yet, unidentified mechanism. 
Controversy surrounding Foxp3 expression in TECs 
As mentioned previously, TEC expression of Foxp3 has become a topic of 
controversy. Data from three transgenic mice refute Foxp3 function in TECs. 
The GFP/Foxp3 fusion protein could not be detected in TECs isolated from Foxp3GFP 
reporter mice10. Liston and colleagues analyzed CD45neg TECs from Foxp3GFP reporter mice 
by flow cytometry. All CD45neg cells were negative for GFP, indicating the absence of Foxp3 
protein from TECs11. 
Liston et al11 suggested that the colocalization between Foxp3 protein and the cortical 
TEC marker keratin-8 detected by Chang el al1 might have been wrongly interpreted. They 
suggested two reasons that Foxp3 might have appeared to be contained within TECs. First, 
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TECs and developing thymocytes form close associations. Second, high immufluorescence 
background staining might have obscured results. Observations of Foxp3 in thymic nurse 
cells (TNCs) support Liston’s suggestion. TNCs are a specialized cell type that closely 
interacts with immature thymocytes in the thymic cortex. Immunofluorescence staining 
plainly showed Foxp3pos cells contained within TNC/thymocyte complexes34. 
Cre/lox elimination of Foxp3 expression in CD4 and FoxN1 expressing cells provide 
further evidence against a TEC-intrinsic function for Foxp3. CD4pos cell-specific ablation of 
Foxp3 in CD4-Cre Foxp3lox mice recapitulated the lymphoproliferative symptoms seen in 
Foxp3-/- mice10. FoxN1-specific ablation of Foxp3 from TECs did not cause autoimmunity11. 
In contrast to data that challenges Foxp3 expression and function in epithelial cells, 
Foxp3 protein was detected in mammary, lung and prostate epithelium of Rag2-/- mice, but 
not in Rag2-/-Foxp3Sf mice14. Also, abundant evidence demonstrates loss of FOXP3 tumor 
suppressor function in human mammary carcinomas15,35. Somatic mutations and deletions of 
FOXP3 were apparent in multiple human breast cancer tissue samples and cell lines15. 
Experiments showing that FOXP3 expression is turned on by p53 during the DNA damage 
response could explain the presence of Foxp3 in epithelial tissues36. Neither p53- nor DNA 
damage-induced Foxp3 investigations have yet been reported for TECs. Interestingly, 
inhibition of p53 is a strategy that is currently being evaluated in mice as a means of 
protecting TECs during chemoradiotherapy and bone marrow transplant37,38. Successful 
rescue of TEC function by p53 inhibition begs more questions as to the relationship between 
p53, Foxp3, Her2/neu, and TEC biology. 
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Finally, age-dependent Foxp3 function in TECs is another possible mechanism that 
could explain the lack of autoimmunity in FoxN1-Cre Foxp3lox mice. Female scurfy carriers 
up to one year old are healthy, but retired female breeders heterozygous for Foxp3Sf formed 
spontaneous mammary tumors sometime within two years of age15. Taken together, these 
data suggest that the tumor suppressor function of Foxp3 is needed between one and two 
years of age in breast epithelial cells. If similar mechanisms regulate Foxp3 across epithelial 
cells, then TEC function in FoxN1-Cre Foxp3lox mice needs to be observed past age one, but 
Liston’s analysis may not have extended longer than four months11. 
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Figure 3.1: Foxp3 and Her2/neu expression in TEC lines. 
The TEC lines were grown under routine culture conditions and 5x104 cells were collected at 
time of passage (~80-90% confluency). 5x105 thymoctes were freshly isolated from an eight 
week old C57/BL6 mouse. Cell pellets were washed in PBS, immediately lysed in Qiagen 
RLT buffer and stored at -80°. mRNA was isolated by using a Qiagen RNeasy kit, according 
the manufacturer’s instructions. One third of the volume of eluted mRNA (10 µl out of 30 µl) 
was used to prepare cDNA. Reverse transcription (RT) reactions were performed with 
random decamer primers, dNTPs, and M-MLV reverse transcriptase in the presence of 
RNase inhibitor (total volume 20 µl). 1/10th of the RT reaction was used in PCRs for Foxp3 
and Her2/neu. cDNA was diluted 1000-fold for 18S PCRs. All genes were measured using 
TaqMan primers from Applied Biosystems. Relative quantities were derived from CT values 
using a standard curve generated by measuring 18S in serially diluted cDNA from adult 
thymocytes. Normalization over 18S accommodated for differences in mRNA input. This 
experiment was performed twice. 
A. Foxp3 mRNA was detected in TEC lines by realtime PCR and expression was 
normalized against 18S. 
B. Her2/neu/18S was plotted against Foxp3/18S. A power regression analysis (log10(y)= 
m + b log10(x), where m=slope and b=y intercept) was performed to assess the 
relationship between Her2/neu and Foxp3 across TEC lines. 
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Figure 3.2: Western blot for Her2/neu and Foxp3 protein in transduced cortical TEC-
like 1308 cells. 
The cortical TEC-like line, 1308, was transduced with pHSPG (vector) and pHSPG-Foxp3 
retrovirus (RV). Transduced cells were grown under routine culture conditions and GFP 
expression was measured to determine transduction efficiency. Vector- and pHSPG-Foxp3-
transduced cells were 71% and 80% GFPpos, respectively. 2x106 cells were collected at time 
of passage (~80-90% confluency). 293T cells were transfected with plasmids for pHSPG 
(vector) and pHSPG-Foxp3 using the Qiagen Effectene protocol. Routine western blot 
procedures are described in Methods and Materials, Western blot and antibodies. Her2/neu 
was detected with a rabbit polyclonal antibody from NeoMarkers (Rb-103-P, diluted 1:1000). 
The membrane was stripped and reprobed to detect Foxp3 using rabbit α-Foxp3 serum 
diluted 1:2000. The membrane was stripped and reprobed again with a mouse monoclonal 
antibody against β-actin (Sigma, AC-74, 1:10,000). This experiment was performed twice. 
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Figure 3.3: Effect of Foxp3 on Her2/neu expression in 427 and 1307 TEC lines. 
Sub-capsular 427 TECs and medullary 1307 TECs were transduced with pHSPG or pHSPG-
Foxp3 retrovirus (RV). Transduction efficiency was determined based on GFP expression 
and is listed above. mRNA was isolated and used to make cDNA as described in Figure 3.1. 
1/10th of the cDNA reaction was serially diluted 10-fold, three times. The Her2/neu PCRs 
contained 1/10th, 1/100th, and 1/1,000th of the cDNA reaction and the HPRT PCRs contained 
1/100th, 1/1,000th, and 1/10,000th of the cDNA reaction. 1/6th of each PCR was run out on a 
1.5% agarose gel. Relative band densities were determined using Image Quant software (OS, 
over saturated, NA, not applicable). Band density was normalized against a background 
value for each individual gel. The relative amount of Her2/neu expression in each sample is 
determined by taking the ratio of Her2/neu over HPRT. This experiment was performed 
twice. 
A. Foxp3 overexpression with pHSPG RV repressed Her2/neu gene expression in 
subcapsular 427 TECs. 
B. Foxp3 overexpression with pHSPG RV had no effect on Her2/neu gene expression in 
medullary 1307 TECs. 
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Figure 3.4: pLL5.0-sh-mFoxp3 design and mouse Foxp3 knockdown. 
The pLL5.0-sh.mFoxp3 vector was designed to selectively knockdown (KD) mouse Foxp3 
and not affect human FOXP3 expression. 
A. Diagram of pLL5.0-sh-mFoxp3 lentiviral vector. The sh-mFoxp3 target sequence was 
selected using siDESIGN® Center, an online siRNA design tool created by 
Dharmacon. For further details, see Methods and Materials, Generation of mouse 
Foxp3 short hairpin RNA construct. 
B. Western blot showing efficient and specific KD of Myc/mFoxp3 protein and 
resistance of human FOXP3 to KD. 293T cells were co-transfected with pLL5.0-sh-
mFoxp3 or pLL5.0-NS (not specific) and either pcDNA-Myc/hFOXP3 or pcDNA-
Myc/mFoxp3. This experiment was performed once. 
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Figure 3.5: Chromatin remodeling inhibitors repress Her2/neu and enhance Foxp3 
expression in subcapsular-like TEC line 427. 
Subcapsular-like TEC 427 cells were plated at a density of 3x105 cells/well in 6-well plates. 
The next day, adherent cells were treated with chromatin remodeling inhibitors: TSA (1 µM), 
AZA (1 µM), or drug vehicle, DMSO. After 24 hours, cell pellets were collected and washed 
with PBS. mRNA was prepared and analyzed as has been described in Figure 3.1. * indicates 
p<0.05 for two-tailed Student’s t-test for drug-treated cells compared to DMSO controls. 
These experiments were performed twice and data shown is representative. 
A. AZA treatment represses Her2/neu expression in 427 cells. 
B. TSA treatment represses Her2/neu expression in 427 cells. 
C. AZA treatment enhances Foxp3 expression in 427 cells. 
D. TSA treatment enhances Foxp3 expression in 427 cells. 
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Figure 3.6: Effect of GW57 on thymocyte number in unmanipulated E14 thymic lobes. 
Thymic lobes were removed from E14 pups and cultured for three weeks in mFTOC media 
with DMSO vehicle or increasing doses of the dual EGFR/Her2/neu inhibitor, GW57 (1 µM, 
5 µM, or 25 µM). Cell number/lobe was determined by running samples on a Gauva 
EasyCyte cell counter in the presence of Gauva ViaCount reagent, a cell viability dye. For 
further details, see Methods and Materials, Fetal thymic organ culture (FTOC) and analysis. 
* indicates p<0.05 for two-tailed Student’s t-test for GW57-treated lobes compared to DMSO 
controls. This experiment was performed once. 
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Figure 3.7: Effect of GW57 on thymocyte differentiation in unmanipulated E14 thymic 
lobes. 
E14 thymic lobes were cultured and harvested as described in Figure 3.6. Each sample was 
stained for markers of thymocyte maturation and analyzed by FACs. CD4-FITC, and CD8-
PERCP were used to differentiate thymocyte maturation stages. Single stain controls were 
used to set gate boundaries. The percentage of cells in each quadrant and the total cell 
number/lobe were used to calculate the number of each cell population per lobe. * indicates 
p<0.05 for two-tailed Student’s t-test for GW57-treated lobes compared to lobes in DMSO. 
This experiment was performed once. 
A. Representative CD4 and CD8 staining and boundaries. 
B. Effect of GW57 on the number of DN (double negative) thymocytes/lobe. 
C. Effect of GW57 on the number of DP (double positive) thymocytes/lobe. 
D. Effect of GW57 on the number of CD4 SP (single positive) thymocytes/lobe. 
E. Effect of GW57 on the number of CD8 SP thymocytes/lobe. 
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Figure 3.8: Whole body irradiation increases Her2/neu expression in the thymus. 
Adult mice were subjected to 500 Rads γ-irradiation. Three days later, the animals were 
sacrificed. The thymus organ was removed and stripped of fatty tissue. Thymocytes were 
removed from the stromal tissue by compressing and twisting the tissue between frosted 
glass slides. Protein lysates from the remaining thymic stoma were released with NP-40 lysis 
buffer. Western blot analysis was performed as described in Figure 3.2. 
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Figure 3.9: Fetal thymic organ culture (FTOC) experimental design. 
2dG, 2-deoxyguanosine, GW57, GW572016. 
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Figure 3.10: Effects of thymic stroma irradiation on thymocyte output. 
Thymic lobes were treated as outlined in Figure 3.9 and harvested according to the same 
protocol described in Figure 3.6. The data was subjected to a Student’s two tailed t-test using 
a p<0.05 and was not found to be statistically significant (NS, no significance). This 
experiment was performed once. 
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Figure 3.11: Differential Effect of GW57 on non-irradiated and irradiated lobes. 
Thymic lobes were treated as described in Figure 3.9 and analyzed as described in Figure 3.6. 
* indicates p<0.05 for two-tailed Student’s t-test for GW57-treated lobes compared to DMSO 
controls. This experiment was performed once. 
A. Thymocyte number per lobe in non-irradiated lobes. 
B. Thymocyte number per lobe in lobes treated with 500R γ radiation. 
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Figure 3.12: Effect of GW57 on thymocyte differentiation in irradiated lobes. 
Thymic lobes were treated as described in Figure 3.9 and analyzed as described in Figures 
3.6 and 3.7. * indicates p<0.05 for two-tailed Student’s t-test for GW57-treated lobes 
compared to DMSO controls. This experiment was performed once. 
A. Percent double negative (DN) cells. 
B. Percent double positive (DP) cells. 
C. Percent CD4 single positive (SP) cells. 
D. Percent CD8 single positive (SP) cells.
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FUTURE DIRECTIONS 
FOXP3 AND SIVA FUNCTION IN T CELLS 
In chapter two, I explored the physical and functional interaction between FOXP3 
and Siva. The impact of this study would be greatly improved by more primary cell data 
pertaining to both the biochemical and putative functional interaction. 
Siva and FOXP3 gene regulation in primary CD4 T cells 
I would like to use primary CD4 T cells to evaluate the contribution of Siva to 
gene regulation in T cells and Tregs. I will test the effects of Siva knockdown (KD) on 
gene expression in sorted CD4posCD25neg and CD4posCD25pos T cells. In addition to 
investigating IL-2 repression in primary T cells, I would like to look at whether Siva KD 
affects GITR, CD25, and CTLA4, known FOXP3 targets associated with Treg.function1,2. 
Refining FOXP3’s Siva-interacting domain 
I stated in chapter two that FOXP3 L.Zip point mutants should be tested for Siva 
binding ability. Additionally, I would like to compare the relative Siva-binding efficiency 
of FOXP3-ZnF-L.Zip-Fkh (AAs 199-431) and FOXP3-L.Zip-Fkh (242-431) mutants to 
the mutants shown in Figure 2.4 (Siva-binding capacity is contained within a central 
portion of the FOXP3 protein (AAs 106-332)). Also, I would like to make an additional 
N-terminal truncation (AAs 150-431) because I am interested in the repressor region 
between FOXP3 AAs 106-199. This transcriptional repressor region is associated with 
binding between FOXP3 and other gene-repressor partners (HDAC7, TIP603, Eos4, and 
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NFAT2). The Foxp3:p65 interaction, which could be functionally related to the 
FOXP3:Siva interaction, has not been mapped to a particular FOXP3 domain5. 
Explanation of Siva mapping data 
The earliest, reproducible Siva:FOXP3 co-immunoprecipitation (Co-IP) datasets 
showed that the Siva ΔZnF mutant and C-terminus mutants bound to FOXP3. Based on 
this data, I predicted that the minimal region shared in common by both mutants, the B 
box domain, would be sufficient to bind FOXP3. Binding between FOXP3 and the Siva 
B box domain alone is extremely weak, but enhanced compared to the FOXP3 negative 
control co-IP. The weak binding between FOXP3 and the Siva B box cannot be due to 
reduced expression levels, as I repeatedly observed high levels of EGFP/Siva B box 
fusion protein in transfected 293T cell lysates. Another possible caveat is that the Siva B 
box sequence is short (34 amino acids) and might not form the three dimensional 
structure that could be necessary for FOXP3-binding when expressed as an EGFP-fusion 
protein. Binding between the Siva ΔB box mutant and FOXP3 indicates that the B box 
portion of the C-terminus is not required for Siva binding to FOXP3. The fact that 
mutants missing either the Zinc-Finger or B box domain sustain FOXP3 binding suggests 
some redundancy in this region. 
TECHNICAL LESSONS LEARNED 
Siva protein detection issues 
Siva protein detection difficulties limited progress with FOXP3:Siva hemi-
endogenous co-IP experiments. When I first started the Siva project, I performed a series 
of optimization experiments and determined that the antibody worked best at 1:1,000 in 
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TBS-0.1% Tween/5% Milk. Even though the antibody worked most of the time, it seems 
unreliable compared to other antibodies I have used. On the other hand, my impression of 
antibody unreliability may actually be related to endogenous Siva instability in Jurkats. 
When probing Jurkat lysate western blots (WBs) with α-Siva, I routinely observed 
heavy bands around 50-70 kD and a single band just below the 31 kD marker. Siva is 
predicted to be 18.8 kD, so I accepted that the 31 kD band was monomeric Siva. Support 
for this interpretation came from Jurkat cells expressing shSiva, where the 31kD band 
was reduced in the Siva KD cells compared to controls. However, I also observed that the 
50-70 kD signal intensity decreased slightly in the Siva KD cells suggesting that those 
bands might derive from un-reduced Siva containing complexes, instead of cross-reactive 
bands. I was not able to resolve this issue because since January, I have not been able to 
detect either the 50-70 kD bands or the band below 31 kD with the α-Siva antibody. 
After returning from vacation last winter, cell recovery from freezing was slow. I 
noticed excessive amounts of debris in the culture even one week after thawing the cells. 
After discussing cell viability issues with another colleague who was working with 
Jurkats, I switched from Fetalplex serum (FPX), a formulated serum complex, to fetal 
bovine serum (FBS). The Jurkat cell viability immediately improved and I performed 
transductions in order to express Myc/FOXP3 and carryout the hemi-endogenous co-IP 
experiments. 
At this point, I was testing whether a sepharose bead pre-clear step would 
minimize the presence of Siva in negative control co-IPs. I obtained weak WB signals for 
these experiments and I initially thought the problem could be due to a WB reagent or the 
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pre-clear step. I performed two co-IP experiments before realizing that the Jurkat cells 
might be the source of my problem. 
My concerns about Siva protein stability in Jurkats are based on reports showing 
that two separate pathways inhibit Siva by ubiquitin-mediated proteasomal degradation. 
One group showed that LPA growth factor binding to the LPA2 receptor caused Siva 
degradation in transfected NIH3T3 cells. Siva expression was restored by serum 
withdrawal6. Since, Jurkat cells express the LPA2 receptor7 and LPA is contained in some 
serum sources, I suspected that the serum switch might have caused Siva protein 
degradation. I switched half of the cells I was growing back to FPX for a week and 
observed a decline in viability. However, when I compared Siva expression between 
FPX-Jurkat lysates to FBS-Jurkat lysates, I still did not detect the ~31 kD band by WB. 
The higher MW bands seemed to be slightly enhanced by FPX compared to FBS, but the 
overall WB intensity was still weaker than what I observed in WBs last fall. This issue 
remains unresolved. 
Thymopoiesis project 
After moving to a new project, I finally learned where I had previously made 
mistakes and bad decisions that prevented progress on the thymopoiesis project. The 
example listed below illustrates how I had a tendency to try short cuts that ultimately led 
to greater confusion and time wasted. 
In addition to the FTOC model described in Chapter Three, I also used the 
OP9DL1 co-culture system to study thymopoiesis. Based on data discussed in Chapter 
Three, I had hypothesized that Foxp3 expression in OP9DL1 cells would affect in vitro 
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thymopoiesis. The experimental design was straightforward: transduce OP9DL1 cells 
with mFoxp3 retrovirus or vector and then test OP9DLI-mFoxp3 cells for their ability to 
support thymopoiesis. Because OP9DL1 cells already express GFP, I used a retroviral 
vector, pHSP4, which expresses truncated human CD4 (the intracellular domain was 
removed leaving only the transmembrane and extracellular domains) as a selection 
marker. 
One of my biggest problems at the beginning of my training was obtaining high 
titer retrovirus by calcium phosphate transfection. I tried ‘fixing’ these problems, but 
ended up creating other obstacles for myself.  
When I first transduced OPDL1 cells, the transduction efficiency was very low. A 
number of protocol changes could have remedied this: titering the retrovirus, improving 
the retrovirus yield by using lower passage 293T cells, and concentrating retrovirus 
particles by ultracentrifugation. Multiple factors contribute to successful retrovirus 
production. At various times, I and other lab members tested calcium phosphate 
transfection protocol variables (buffers and plasmids), but made limited progress. 
Eventually, with the help of a new post-doc, we saw that early passage 293T cells would 
dramatically improve retrovirus production (passage 1-10 vs. passage 30-40), whereas 
other factors (buffers and plasmids) seem to withstand longer four-degree storage periods 
without altering retrovirus titer. 
Next, I tried to accommodate low transduction efficiency by selecting for 
transduced clones by limiting dilution (0.5 cells/well in 96-well plates). In retrospect, I do 
not think this is a good strategy for OP9 cells. According to T. Nakano and colleagues 
 148 
who have worked extensively with OP9 cells to study embryonic stem cell 
differentiation, “OP9 cells can easily lose the ability to maintain lympho-
hematopoiesis.”8 The OP9DL1 cells may have lost the ability to support hematopoiesis 
during the clonal selection process. Unfortunately, I did not consider this until afterwards 
and did not include a non-clonal OP9DL1 monolayer, which would have been the 
appropriate control. I obtained OP9DL-P4 and OP9DLI-P4-mFoxp3 clones and tested 
four of them for their ability to support thymocyte differentiation. Two of the Foxp3pos 
clones failed to form a monolayer by 24-hours after plating. Neither of the remaining 
clones supported thymocyte differentiation. 
PERSPECTIVE 
I spent about three years studying thymopoiesis and another three years 
investigating the biochemical and functional interaction between Foxp3 and Siva. At the 
end, I am most curious about Siva functions that may be Foxp3-independent. Does Siva 
affect thymopoiesis or hematopoiesis? Could Siva somehow be implicated in hyper 
immune activation associated with CD70:CD27 signaling? Answers to some of these 
questions could inform future investigations regarding a putative functional interaction 
between Foxp3 and Siva. 
SIVA AND THYMOPOIESIS 
The question of Siva’s potential role in thymopoiesis was first raised by the 
observation that double positive (DP) thymocytes express high levels of Siva protein9. 
Since then, no reports about Siva function in the thymus have been published. 
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Siva is pro-apoptotic and thymopoiesis is a highly selective process that relies on 
apoptosis to remove around 97% of thymocytes initiated. Other pro-apoptotic factors are 
known to sensitize thymocytes to death by neglect. 
Siva’s pro-apoptotic function is associated with Bcl-2 family members and these 
factors are associated with various thymopoiesis checkpoints. Siva promotes 
mitochondrial-dependent apoptosis by binding and inhibiting Bcl-2 and Bcl-XL. Bcl-2 
overexpression rescues thymopoiesis in IL-7 signaling-deficient mice, but neither Bcl-2 
nor Bcl-XL is required for thymopoiesis. Instead, the pro-survival Bcl-2 family member, 
Mcl-1 provides an essential survival signal during thymopoiesis. Mcl-1 deficient mice 
arrest at the DN stage and Siva is highly expressed at the subsequent DP stage, provoking 
the speculation that the balance between Siva and Mcl-1 contributes to TCRβ selection. 
The region of Bcl-2/Bcl-XL required to interact with Siva has not been identified, 
so domain information cannot be used to predict whether Mcl-1 and Siva might 
physically interact. Anti-apoptotic Bcl-2 and Bcl-XL each contain BH (Bcl-2 homology) 
domains 1-4 and a transmembrane domain (TMD). Pro-apoptotic Bax contains a TMD 
and BH domains 1-3. Bax does not interact with Siva, which invites the hypothesis that 
the BH4 domain could mediate Siva-binding. Mcl-1 is the only known pro-survival Bcl-2 
family member that lacks a transmembrane domain; it contains BH1 and BH3 domains9-
13. 
Based on the known pro-apoptotic function of Siva, I would predict that 
thymocyte-specific knockdown should positively affect thymocyte number and 
negatively affect DP thymocyte deletion. This question could be tested in the FTOC 
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system described in Chapter Three. Given the complex relationship between different 
thymic lymphoid and stromal cell populations, I would investigate Siva’s effect on 
thymocyte distribution by analyzing all known thymic lymphoid populations (double 
negative, double positive, CD4 single positive, CD8 single positive, Treg, natural killer T 
cells, and γδ T cells). Also, I would perform histology to evaluate thymic cortico-
medullary organization. 
In addition to possibly contributing to thymopoiesis, gene array data suggests that 
Siva could be involved in hematopoiesis separate from thymopoiesis. The mouse BioGPS 
gene atlas showed Siva expression to be extremely high in stem cell lines and in 
hematopoietic progenitor cells compared to other cell populations assayed14,15. 
Myelopoiesis can be induced in vitro by adding cytokines and growth factors to the 
culture media. NK, B, and T cell development requires cytokines and stromal cell 
support. OP9 stromal cells support NK and B cell development because M-CSF is 
absent16. Notch ligand, expression (DL1 or DL4) enables OP9 cells to support T cell 
development, though not past the DP stage17. Therefore, well-characterized experimental 
systems are available that could be used to study Siva’s contribution to the differentiation 
of multiple HSC lineages. 
CD27, SIVA EXPRESSION AND T CELL APOPTOSIS 
Siva was first identified as a binding partner for the CD27 co-receptor, but a 
functional interaction between CD27 and Siva has not yet been observed in T cells under 
physiological conditions. Siva overexpression in HPB-ALL T lymphocytes enhanced 
apoptosis in response to CD27 ligation by CD70 in vitro18. Transgenic mouse data and 
 151 
adoptive transfer experiments associate the CD27:CD70 axis with chronic T cell 
activation19. In vitro, Siva negatively regulates T cells by inhibiting NFκB and IL-2, and 
by enhancing apoptosis20,21. Thus, in vitro data predicts that, in the presence of Siva, 
ligation of CD27 by CD70 would promote apoptosis and inhibit T cell activation. Instead, 
in vivo blockade of CD70 protects mice from colitis and arthritis. 
One explanation that could resolve Siva in vitro data with CD27:CD70 in vivo 
data is inhibition of Siva by ubiquitin-mediated proteasomal degradation. LPA2 (Edg4), a 
G-protein coupled growth factor receptor and XIAP, an anti-apoptotic E3 ligase, both 
inhibited Siva function by ubiquitination and proteasome-dependent mechanisms in 
vitro6,20. LPA2-mediated Siva degradation required LPA stimulation. Growth factor 
withdrawal restored Siva expression6. Though the LPA2 experiments were not performed 
in a lymphocyte line, LPA2 is expressed by T cells and has been shown to mediate T cell 
migration7. A possible physiological scenario could exist where LPA supports survival of 
CD27pos T cells by inhibiting Siva expression. Support for such a possibility requires 
more data pertaining to the expression kinetics and immunobiology of LPA, LPA2, Siva, 
CD27, and CD70. 
FINAL COMMENT 
For a long time I was attracted to big questions that seemed to necessitate 
complex model systems and experimental time courses requiring weeks or months. But 
once I started to generate reliable data for myself using simple transcriptional assays, my 
attraction to in vivo systems diminished. I finally experienced the thrill that can happen 
when there is a steady pace between the idea, the hypothesis, an experiment, the data, and 
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back again. I expect that if I only did three-day long luciferase assays, I would soon get 
bored, but it is tempting to exhaust any experimental system that yields quick and reliable 
results. Even so, the limitations of in vitro systems need to be respected and models 
inspired by in vitro data should be subjected to questions concerning in vivo relevance. 
I’ve always been comfortable and relatively succussful in traditional academic 
settings. Bench science was challenging for me, but I do not think I could have learned 
the lessons I gained in any other way. One must learn to balance the rational with the 
irrational. That is, one must do one’s best to logically incorporate controls to 
accommodate all known variables, but be able to accept that unaccounted variables may 
remain. That is where discovery happens. If we insist on being able to explain why every 
result is the way it is, then we may blind ourselves to learning something that lies outside 
of our predictions. 
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